Document:

Exhibit 10.4

 Exhibit 10.4 
 EXECUTION VERSION 
 IRREVOCABLE UNDERTAKING 
 This irrevocable undertaking (this “Undertaking”) is made on May 25, 2007 
 BETWEEN: 
  

	(1)	The Nasdaq Stock Market, Inc., a company duly incorporated and organized under the laws of Delaware, having its principal office at One Liberty Plaza, New York, NY 10006, USA
(“Nasdaq”); and 

  

	(2)	Magnus Böcker, having social security number 610830-6611, Baldersgatan 4, 114 27 Stockholm, Sweden (the “Shareholder”). 

 Nasdaq and Shareholder are hereinafter collectively referred to as the “Parties” and individually as a “Party”. 
 BACKGROUND: 
 (A) Nasdaq intends to make a public tender
offer to the holders of shares in OMX AB, a company duly incorporated and organized under the laws of Sweden, with corporate registration number 556243-8001 (“OMX”), to tender all of the shares in OMX on the terms and conditions set forth
in the press release (the “Offer”) attached as Appendix A (the “Offer Announcement”). 
 (B) Shareholder is the
owner of 140.822 shares (the “Shares”) in OMX, and has, in order to encourage Nasdaq (“the Offeror”) to make the offer, agreed to make the irrevocable undertaking contemplated herein. 
 IT IS AGREED as follows: 
  

	1	Shareholder’s Undertaking 

  

	1.1	Shareholder represents and warrants that it is the owner of, and has all relevant authority to accept (or procure the acceptance of) the Offer in respect of, the Shares, which
Shares are free and clear of encumbrances of any kind. 

  

	1.2	Subject only to Section 4, Shareholder hereby irrevocably undertakes to (i) accept (or procure the acceptance of) the Offer (subject to having the benefit of any
improvement of the Offer granted to other OMX shareholders) in respect of all Shares immediately prior to, but conditioned upon, the Offer being declared unconditional (taking into account, for purposes of the acceptance level condition, the
Shares), (ii) deliver (or procure the delivery of), evidence of such acceptance reasonably agreed upon by the Parties, (iii) upon acceptance of the Offer, elect to receive 100 per cent newly issued Nasdaq shares, and no cash, as
consideration for the Shares, in accordance with a mix and match facility of the Offer as long as the mix and match facility includes an equalizing mechanism designed to achieve substantially similar value between the alternatives of cash, shares or
a combination of cash and shares as of the calculation date (Shareholder acknowledges that, to the extent valid elections for new Nasdaq shares under the mix and match facility cannot be satisfied in full, they will be scaled down on a pro rata
basis and compensated in cash), (iv) unless and until the Offer lapses or is withdrawn, support Nasdaq, to a reasonable extent and where capable of doing so, in its implementation of the Offer, and 

 
to exercise all voting rights attaching to the Shares in such manner as to enable the Offer to become unconditional and to oppose the taking of any action or
approval of any resolution which may result in any condition of the Offer not being satisfied or which may otherwise prejudice or frustrate the Offer and (v) to the extent that any of the Shares are not registered in its name, to procure the
registered holder(s) to act in accordance with the terms of this Undertaking. 
  

	1.3	Subject only to Section 4, Shareholder hereby irrevocably undertakes to not, unless and until the Offer lapses or is withdrawn: (i) offer, sell, transfer, charge, pledge
or grant any option over or otherwise dispose of any of the Shares, whether directly or indirectly, except to Nasdaq under the Offer, (ii) accept any other offer in respect of any of the Shares, (iii) directly or indirectly solicit
proposals or offers from third parties for the acquisition of all shares in OMX, (iv) propose or vote in favor of any resolution for payment of dividends or other value distributions by OMX (whether in cash or otherwise and whether to the
shareholders of OMX or to a third party), or propose or vote in favor of any other resolution, or take any action or make any statement, which could prejudice or frustrate the Offer, or (v) withdraw the acceptance referred to in
Section 1.2 above in respect of any of the Shares. 

 It is understood that Shareholder undertakings are not applicable to
or bind any of the individual board members of OMX acting in such capacity. 
  

	2	Nasdaq’s Undertaking 

  

	2.1	As set out in the Offer Announcement regarding the indicative time table for the Offer, the completion of the Offer is conditional upon the satisfaction of certain conditions, which
will be affected by Hart Scott Rodino waiting period, anti-trust and full regulatory approvals and Nasdaq shareholder approval. Nasdaq and OMX expects the Offer to be completed by year-end 2007. Nasdaq undertakes to use best reasonable efforts to
procure that such indicative time table will be met. 

  

	2.2	If the Shareholder has tendered the Shares in the Offer and the Offer is consummated, Nasdaq shall not offer, contract to sell, sell, transfer, or grant any option, right or
contract to purchase or otherwise dispose of all or any of the shares in OMX (other than to any entity controlling, controlled by, or under common control with the Offeror during the period in which this Section 2.2 is operative) within a
period of nine months after consummation of the Offer. 

  

	3	Condition precedent 

 A condition precedent for this
Undertaking to enter into force is that: 
 (a) the Offer is made through a public announcement of the Offer Announcement on or before
25 May, 2007 and 
 (b) the Offer is recommended by the board of directors of OMX, and 
 (c) Nordea Bank AB and Investor AB entering into irrevocable undertakings similar to this one; in the absence of which Shareholder will have no
obligations hereunder. 
  

 2 

	4	Termination 

  

	4.1	This Undertaking shall terminate automatically and be of no further force or effect if (i) the Offer lapses or is withdrawn or the terms and conditions of the Offer, as
described in the Offer Announcement, are substantially changed in a manner materially adverse to OMX shareholders without the prior written consent of Shareholder, provided that this shall not apply to any waiver by Nasdaq of any of the conditions
of the Offer, (ii) prior to the Offer being declared unconditional, a bona fide unsolicited third party public offer is made for the all shares in OMX which corresponds to an offer value in SEK equal to or exceeding SEK 220 per OMX share,
or (iii) prior to the Offer being declared unconditional, the value of the Offer, as accepted by the Shareholder in accordance with Section 1.2, would equate to less than SEK 190 per OMX share during a period of fifteen
(15) consecutive trading days, based on the volume weighted average price of the Nasdaq share during such period (as derived from the Nasdaq Global Select Market) and the currency conversion shall be calculated based on the average USD/SEK
exchange rate over the fifteen (15) consecutive trading days, as derived from the European Central Bank daily foreign exchange reference rate at close of business. 

  

	4.2	For the purposes of determining the offer value of such third party offer referred to in Section 4.1 (ii) above, if (i) there are any rights to elect to receive
different forms of consideration in such third party offer, and if such third party offer contains a basic offer comparable to the terms of the Offer assuming no mix and match facility was offered, then the value of such basic offer shall be elected
for the determination of the offer value and any alternative forms of consideration shall be disregarded, (ii) the consideration under such third party offer consists (wholly or partly) of listed securities, the offer value shall be calculated
by reference to the quotation or price (as derived from the relevant exchange) of such securities at the close of business on the trading day immediately preceding the date the third party offer was publicly announced and (iii) the currency of
the consideration under such third party offer is not SEK, the currency conversion shall be calculated based on the third-party-offer-consideration-currency/SEK exchange rate on the day immediately preceding the date the third party offer was
publicly announced, as derived from the European Central Bank daily foreign exchange reference rate at close of business. 

  

	4.3	All the Shareholder’s obligations will lapse, at the option of the Shareholder, if 

 (a) the Registration Statement on Form S-4 in relation to the Offer not being completed and submitted to Securities and Exchange Commission on or before August 15, 2007; 
 (b) Nasdaq waives the acceptance level condition and declares the Offer unconditional without the Shareholder’s consent and at the time of such
waiver has not reached an acceptance level of 2/3 of the OMX shares (including shares subject to irrevocable undertakings, whether yet delivered for acceptance or not); 
  

 3 

 (c) during the term of this Agreement, any dividend is declared by Nasdaq without the Shareholder’s
consent prior to the Offer being completed or having lapsed or been withdrawn; 
 (d) the recommendation of the Offer by the board of OMX
being withdrawn; 
 (e) the Offer is not being declared unconditional before December 15, 2007; 
 (f) if a material adverse change in Nasdaq’s financial position or operation, which could not have been reasonably known or anticipated by
Shareholder at the time of entering into this undertaking, has become known to the Shareholder and could have a materially adverse effect on Nasdaq’s liquidity, sales, results, equity or stock price; or 
 (h) any information made public by Nasdaq or disclosed by Nasdaq to Shareholder or OMX is materially inaccurate, incomplete or misleading. 
  

	5	Miscellaneous 

  

	5.1	Any public disclosure of the existence or contents of this Undertaking will need to be agreed in advance between the Parties, except (a) as required by applicable law or stock
exchange regulation, in which case the Party required to disclose information hereof shall to the extent reasonably practicable consult with the other Party prior to such disclosure and (b) in the ordinary course in connection with the investor
relations practices of the Parties. The Parties agree that this Undertaking shall be disclosed in full in the offer documentation to be prepared by Nasdaq for the Offer. 

  

	5.2	Each of the Parties confirms that this Undertaking represents the entire understanding and constitutes the whole agreement between the Parties in relation to its subject matter and
supersedes all prior agreements and understandings, whether oral or written, between the Parties with respect to the subject matter hereof. 

  

	5.3	This Undertaking may only be amended by an instrument in writing duly executed by the Parties. 

  

	5.4	This Undertaking shall be binding upon and inure to the benefit of the successors of the Parties but shall not be assignable by any of the Parties without the prior written consent
of the other Party. 

  

	5.5	This Undertaking is not intended to, and does not, confer upon any person other than the Parties hereto any rights or remedies hereunder. 

  

	5.6	If any provision of this Undertaking or the application of it shall be declared or deemed void, invalid or unenforceable in whole or in part for any reason, the Parties shall amend
this Undertaking as shall be necessary to give effect to the spirit of this Undertaking so far as possible. If the Parties fail to amend this Undertaking, the provision which is void, invalid or unenforceable, shall be deleted and the remaining
provisions of this Undertaking shall continue in full force and effect. 

  

	6	Governing Law and Disputes 

 This Undertaking shall
be governed by and construed in accordance with the laws of Sweden. Any dispute, controversy or claim arising out of, or in connection with, this 

  

 4 

 
Undertaking, or the breach, termination or invalidity of the Undertaking, shall be settled by arbitration in accordance with the Rules of the Arbitration
Institute of the Stockholm Chamber of Commerce. The place of arbitration shall be Stockholm, Sweden. The language to be used in the arbitral proceedings shall be English. 
  

 This Undertaking has been duly executed in two
(2) original copies, of which each of the Parties has taken one (1) copy. 
 Friday, May 25, 2007 
  

									
		  		  		  	THE NASDAQ STOCK MARKET, INC.
			
	/s/ Magnus Böcker	  		  	/s/ Robert Greifeld
	Name:	  	Magnus Böcker	  		  	Name:	  	Robert Greifeld
		  		  		  	Title:	  	President and CEO

  

 5Asset Purchase Agreement

 EXHIBIT 10.30 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED. 
 ASSET PURCHASE AGREEMENT 
 This ASSET PURCHASE AGREEMENT (the “Agreement”) is made as of this 4th day of October,
2004 by and between Glaxo Group Limited, a company incorporated under the laws of England and Wales with offices at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, UK (“GGL”), SmithKline Beecham Corporation, doing
business as GlaxoSmithKline, a company incorporated under the laws of the Commonwealth of Pennsylvania with offices at One Franklin Plaza, 200 North 16th Street, Philadelphia, Pennsylvania 19101 U.S.A. (“SB”) (GGL and SB are collectively referred to in this Agreement as “GSK”), and Jazz Pharmaceuticals, Inc., a company incorporated
under the laws of the State of Delaware with offices at 3180 Porter Drive, Palo Alto, California 94304, U.S. (“Jazz Pharmaceuticals”). GSK and Jazz Pharmaceuticals are referred to herein on occasion separately as a “Party” or
together as the “Parties”. 
 RECITALS 
 WHEREAS, GSK owns intellectual property rights covering a type IIa sodium channel antagonist compound, designated by GSK as GW273293, and other related compounds (hereinafter defined together as the
“Compounds”); 
 WHEREAS, Jazz Pharmaceuticals desires to purchase, and GSK desires to sell, the rights to the Compounds and
certain assets relating to GW273293 including the intellectual property rights covering the Compounds; and 
 WHEREAS, Jazz Pharmaceuticals
desires to [ * ] under the intellectual property rights covering the Compounds for [ * ], as further provided herein. 
 NOW, THEREFORE, in
consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 ARTICLE 1—DEFINITIONS; INTERPRETATION 
 1.1
Definitions. The following terms will have the following meanings in this Agreement: 
  

	 	1.1.1.	“Additional Consideration Payment” has the meaning ascribed to it in Section 3.5. 

  

	 	1.1.2.	“Additional Consideration Payment Statement” has the meaning ascribed to it in Section 4.2. 

  

	 	1.1.3.	 “Affiliate” of a Party means any corporation or other business entity which is directly or indirectly controlling, controlled by, or under common control
with such Party for so long as such control exists. For purposes of this definition, “control” means the direct or indirect ownership of at least fifty percent (50%) of the 

  

 1 

	 	 
outstanding shares or voting interest in such corporation or other entity having the power to vote or direct the affairs of the entity. If the laws of the
jurisdiction in which such entity operates prohibit ownership by a Party of at least fifty percent (50%), “control” will be deemed to exist at the maximum level of ownership allowed by such jurisdiction. Notwithstanding the foregoing, the
owners of preferred stock (or common stock issued upon conversion thereof) of Jazz Pharmaceuticals, such as financial institutions, venture capital funds and private equity investors, will not be its “Affiliates” for purposes of this
Agreement. 

  

	 	1.1.4.	“Agreement” means this Asset Purchase Agreement, together with the Schedules hereto, and any instrument amending this Agreement as referred to in Section 12.7. The
expressions “Article” and “Section” followed by a number mean and refer to the specified Article or Section of this Agreement. 

  

	 	1.1.5.	“Asset Transfer Period” has the meaning ascribed to it in Section 2.4. 

  

	 	1.1.6.	“Business Day” means any day other than Saturday or Sunday on which the New York Stock Exchange is open for business. If not designated as a “Business Day”, a
“day” shall include Saturdays, Sundays and holidays. 

  

	 	1.1.7.	“Closing Date” means the date provided for in Section 5.1. 

  

	 	1.1.8.	“Combination Product” means a product that is a pharmaceutical preparation for human use incorporating two or more therapeutically active ingredients, including a
Compound, as active ingredients. Notwithstanding the foregoing, additives and excipients, including, but not limited to, drug delivery vehicles and formulations, adjuvants, carriers, bulking, stabilizing and flavoring agents, taste-masking agents,
surfactants, antimicrobial agents and antioxidants will not be deemed to be “therapeutically active ingredients,” and their presence will not be deemed to create a Combination Product under this Section 1.1.8.

  

	 	1.1.9.	“Compound(s)” means GSK’s type IIa sodium channel antagonist compound designed by GSK as compound GW273293, any compound covered by the Patents, and all derivatives,
and salts of such Compounds to the extent covered by the Patents. 

  

	 	1.1.10.	“Confidential Information” has the meaning ascribed to it in Section 11.1. 

  

	 	1.1.11.	“Diligent Efforts” means the carrying out of obligations in a sustained manner consistent with the efforts a Party devotes to a product of similar market potential, and
profit potential resulting from its own research efforts, with the objective of launching a Product. Diligent Efforts requires that: (i) the Party promptly assign responsibility for such obligations to specific employee(s) who are held accountable
for progress and monitor such progress on an on-going basis, (ii) the Party set and consistently seek to achieve specific and meaningful objectives for carrying out such obligations, and (iii) the Party consistently make and implement decisions and
allocate resources designed to advance progress with respect to such objectives. 

  

	 	1.1.12.	“Effective Date” means the date of this Agreement as set forth above, which shall be the same date as the Closing Date. 

  

 2 
 [ * ]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

	 	1.1.13.	“EMEA” means the European Medicines Evaluation Agency (European Medicines Agency) and the Committee for Proprietary Medicinal Products (Committee for Medicinal Products
for Human Use) or any successor agency thereof. 

  

	 	1.1.14.	“Europe” or the “EU” means the countries comprising the European Union and includes any of the following twenty-five (25) countries that are members of the
European Union as of the Effective Date, and any other countries that subsequently become part of the European Union as of the date such membership becomes effective, including, Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland,
Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom, Cyprus, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Slovakia and Slovenia. 

  

	 	1.1.15.	“FDA” means the U.S. Food and Drug Administration and any successor agency thereof. 

  

	 	1.1.16.	“First Commercial Sale” of a Product means the first invoiced commercial sale by Jazz Pharmaceuticals, its Affiliates or sublicensees (excluding, however, sales made by
one such entity to another such entity) to a Third Party for commercial purposes in a country after Marketing Approval to market such Product in such country has been granted by the governing health regulatory authority of such country.

  

	 	1.1.17.	“Grantback License” has the meaning ascribed to it in Section 6.1. 

  

	 	1.1.18.	“Gross Sales” has the meaning ascribed to it in Section 1.1.28. 

  

	 	1.1.19.	“Gross Selling Price” means the gross price at which a product is sold to a Third Party before discounts, deductions, credits, taxes, and allowances.

  

	 	1.1.20.	“GW273293” means GSK’s type IIa sodium channel antagonist compound with the chemical structure shown in Schedule 1.1.20. 

  

	 	1.1.21.	“Know-How” means technical and other information that is not subject to published patent rights and that is not in the public domain, including, but not limited to,
information comprising or relating to concepts, discoveries, data, designs, formulae, ideas, inventions, methods, assays, research, procedures, designs for experiments and tests and results of experimentation and testing, including results of
research and development, manufacturing processes specifically related to GW273293, specifications and techniques, chemical, pharmacological, toxicological, clinical, analytical, and quality control data, trial data, case report forms, data
analyses, reports, manufacturing data or summaries relating to the quantities of GW273293 being transferred hereunder, and information contained in submissions to and information from regulatory authorities. Know-How includes documents containing
Know-How. Except as set forth above with respect to manufacturing process specifically related to GW273293, Know-How does not include GSK Know-How relating to manufacturing processes. 

  

 3 
 [ * ]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

	 	1.1.22.	“Licensed GSK Patents” means those GSK patents set forth in Schedule 2.6, attached hereto and incorporated herein. 

  

	 	1.1.23.	“Marketing Approval” means, in any country, all approvals, licenses, registrations or authorizations, (including, in Europe and Canada only, governmental pricing approvals
and governmental formulary acceptance based on pricing approval (but excluding formulary acceptance of private parties)), of any federal regulatory agency, department, bureau or other governmental entity, necessary for the sale of the Product.
Marketing Approval in a country shall be deemed to occur upon first receipt of notice from the FDA, EMEA or similar agency in such country that sale of a Product in such country has been approved, including governmental pricing approval and
governmental formulary acceptance based on pricing approval in Europe and Canada. Marketing Approval in Europe shall include the approval of any Central Marketing Authorization that is filed through the centralized procedure for the EU and approved
by the European Commission. If a Central Marketing Authorization is filed through the centralized procedure for the EU and approved by the European Commission, Marketing Approval for the EU shall be deemed to have occurred when pricing approval is
received in at least one country in the EU. In the countries of Europe and in Canada, “Marketing Approval” shall not be deemed to occur until pricing or formulary approval is obtained. Marketing Approval shall be deemed to have occurred in
such country where government approval of pricing has not been obtained if, at any time, Jazz Pharmaceuticals, its Affiliates or sublicensees makes the First Commercial Sale of Product in the country without obtaining pricing approval, with the date
of MAA approval deemed to have occurred on the date of the First Commercial Sale of the Product in the country. 

  

	 	1.1.24.	“Marketing Approval Application” or “MAA” shall mean a New Drug Application (“NDA”) (as defined in 21 C.F.R. § 314.50 et. seq.), or a
comparable filing for Marketing Approval in a country, in each case with respect to a Product in the Territory. 

  

	 	1.1.25.	“Major Market Country” means any one of the U.S., the United Kingdom, France, Germany, Italy, Spain or Japan. 

  

	 	1.1.26.	“Milestones” mean the events identified in Section 3.3. 

  

	 	1.1.27.	“Milestone Payments” mean the payments to be made by Jazz Pharmaceuticals to GSK pursuant to Section 3.3. 

  

	 	1.1.28.	“Net Sales” means the aggregate gross sales amount (“Gross Sales”) invoiced for Product, as applicable, in the countries of the Territory on which Additional
Consideration Payments are due hereunder, by Jazz Pharmaceuticals, its Affiliates and sublicensees, to Third Parties, 

 (a)
less the following deductions: 
 (i) trade, quantity and cash discounts and rebates allowed and taken by Jazz Pharmaceuticals (and its
Affiliates and sublicensees); 
  

 4 
 [ * ]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 (ii) any adjustments on account of price adjustments, billing errors, rejected goods, damaged goods and
returns; 
 (iii) credits, charge-backs and prime vendor rebates, fees, reimbursements, and similar payments granted or given to wholesalers
and other distributors, buying groups, health care insurance carriers, pharmacy benefit management companies, health maintenance organizations, other institutions or health care organizations or other customers; and 
 (iv) rebates or other price reductions provided, based on sales by Jazz Pharmaceuticals (and its Affiliates and sublicensees) of Product, as applicable,
to any governmental or regulatory authority in respect of any state or federal Medicare, Medicaid or similar programs; and 
 (b) less an
amount equal to all freight, insurance and handling costs, import costs, duties, tariffs, taxes, excises and other governmental charges incurred and paid by Jazz Pharmaceuticals (and its Affiliates and sublicensees). 
 The foregoing deductions from Gross Sales will only be deducted once and only to the extent not otherwise deducted from Gross Sales. Net Sales shall not
include any sales among Jazz Pharmaceuticals, its Affiliates and sublicensees. 
  

	 	1.1.29.	“Patents” means all the GSK granted patents and pending applications covering the Compounds and the processes for making a Compound, or any formulation or use thereof in
the Territory, including any patent term extensions, supplementary protection certificates, registrations, extensions, reissues, reexaminations or divisionals thereof, and including any granted patents arising from the pending applications, which
are listed in attached Schedule 1.1.29. 

  

	 	1.1.30.	“Phase I Clinical Trial” means clinical trials for the first introduction into humans of a Product, including small scale clinical studies conducted in normal volunteers
and/or patients to obtain information on the Product’s safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. 312.21(a). 

  

	 	1.1.31.	“Phase II Clinical Trial” means a human clinical trial that is intended to initially evaluate the effectiveness of a Product in the targeted patient population for a
particular indication or indications in human subjects with the disease or indication under study, as more fully defined in 21 C.F.R. 312.21(b). 

  

	 	1.1.32.	“Phase III Clinical Trial” means a pivotal efficacy trial whose primary objective is to obtain a definitive evaluation of the therapeutic efficacy and safety of a Product
in patients for the particular indication in question that is needed to evaluate the overall risk-benefit profile of a Product and to provide adequate basis for obtaining requisite Marketing Approval(s) and product labeling, as more fully defined in
21 C.F.R. (S) 312.21(c). 

  

 5 
 [ * ]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

	 	1.1.33.	“Product” means any pharmaceutical product that includes a Compound as an active pharmaceutical ingredient. “Product” shall include Combination Products.

  

	 	1.1.34.	“Purchase Price” has the meaning ascribed to it in Section 3.1. 

  

	 	1.1.35.	“Purchased Assets” means the following Assets to be acquired by Jazz Pharmaceuticals pursuant to this Agreement on the Closing Date: 

 (a) the Patents and information and hard-copy (i.e., non-electronic) records used by GSK’s Corporate Intellectual Property group in filing,
prosecuting, reviving, maintaining, renewing, enforcing and defending the Patents, and file wrappers and hard-copy (i.e., non-electronic) correspondence with the patent office in all jurisdictions in which the Patents are pending or granted;

 (b) data (including without limitation, all pharmacological, pre-clinical, clinical, analytical and quality control data), manufacturing
data (including batch records and technical reports) for the quantities of GW273293 being transferred hereunder, results and material correspondence, and other documents relating to the Purchased Assets, all of which are listed on Schedule 1.1.35,
all in electronic form; 
 (c) quantities of GW273293 set forth on Schedule 1.1.35(c), and, to the extent they exist, retained stability
samples of GW273293 and tissue samples used in the toxicology work relating to GW273293; and 
 (d) any Know-How specifically relating to
GW273293 developed, acquired or licensed by GSK prior to the Closing Date, as set forth in Schedule 1.1.35. 
 The Purchased Assets do not
include laboratory notebooks or other specific information pertaining to proof of invention or reduction to practice of GW273293 or the inventions claimed in the Patents. Should Jazz Pharmaceuticals require access to such information for purposes of
responding to a challenge to the validity or enforceability of the Patents, or in order to initiate or participate in an interference proceeding in the United States (or a similar proceeding elsewhere), or to assert the Patents affirmatively against
Third Parties, then in each case GSK shall promptly make such information available at no charge upon the reasonable request of Jazz Pharmaceuticals. 
  

	 	1.1.36.	“ROW” means all countries and territories of the world except the U.S. and Europe. 

  

	 	1.1.37.	“Territory” means all countries and territories of the world. 

  

	 	1.1.38.	“Third Party” means any Party other than GSK or Jazz Pharmaceuticals or each of their respective Affiliates. 

  

 6 
 [ * ]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

	 	1.1.39.	“Time of Closing” means 10:00 A.M. (Pacific Daylight Time) on the Closing Date or such other time and date as the Parties will mutually agree in writing at which time the
Parties are to deliver the closing documents described in Section 5.2. 

  

	 	1.1.40.	“U.S.” means the United States of America, including the Commonwealth of Puerto Rico and the U.S. Virgin Islands. 

  

	 	1.1.41.	“Valid Claim” means a claim of an issued, unexpired Patent which has not been revoked, held to be invalid or unenforceable by a final judgment of a court or other
government agency of competent jurisdiction from which no appeal can be or is taken within the time allowed for appeal and which has not been admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise.

  

	1.2	Interpretation. In this Agreement, words importing the singular number only will include the plural and vice versa, words importing a specific gender will include the other
genders and references to persons will include corporations and one or more persons, their heirs, executors, administrators or assigns as the case may be. In addition, the division of this Agreement into Sections and the insertion of headings are
for convenience of reference only and will not affect the interpretation hereof. 

 ARTICLE 2—PATENT ASSIGNMENT; POST-CLOSING
ASSISTANCE; LICENSE GRANT 
 2.1 Assignment of Patents. On the Closing Date, and subject to the terms and conditions of this Agreement, GSK
will sell, assign, convey, transfer and deliver to Jazz Pharmaceuticals, and Jazz Pharmaceuticals will purchase and accept from GSK, the entire ownership, right title and interest of GSK in and to the Purchased Assets. Within fifteen
(15) Business Days of the Closing Date, GSK will authorize and request the Commissioner or Director of Patents and Trademarks of the United States to issue all U.S. patents that may issue in the future as a result of the Purchased Assets to
Jazz Pharmaceuticals, its successors and assigns, in accordance with this Agreement. 
 2.2 Registration of Purchased Assets. GSK will cooperate with
and reasonably assist Jazz Pharmaceuticals in relation to Jazz Pharmaceuticals’ registration as the new owner of the Purchased Assets in the registers of the respective patent offices in the Territory. GSK will execute and deliver, or cause to
be executed and delivered, at no cost to Jazz Pharmaceuticals, any and all documents reasonably requested by Jazz Pharmaceuticals that may be necessary, in accordance with the rules and regulations of the various patent offices worldwide, to
transfer to Jazz Pharmaceuticals, its successors or other legal representative, GSK’s right, title and interest in and to the Purchased Assets and to register the transfer at the Patent and Trademark Office of the United States and patent
offices in all other territories where patent rights have been granted or are pending. If Jazz Pharmaceuticals elects to record this Agreement or any other documents with the appropriate United States or foreign governmental authorities or
registries, Jazz Pharmaceuticals will bear the costs and fees associated with recording, but GSK will provide timely cooperation to Jazz Pharmaceuticals as reasonably requested at no cost to Jazz Pharmaceuticals. 
 2.3 Post-Closing Assistance. Upon the reasonable request of Jazz Pharmaceuticals, GSK will provide reasonable support to Jazz Pharmaceuticals, at no cost to Jazz
Pharmaceuticals, to 

  

 7 
 [ * ]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 
assist Jazz Pharmaceuticals with the transfer and registration of the Purchased Assets and to respond to official actions relating to the Purchased Assets.
GSK’s obligation to reasonably assist Jazz Pharmaceuticals as provided for under this Section 2.3 will terminate six (6) months after the Effective Date. Thereafter, if Jazz Pharmaceuticals requires the assistance of GSK, Jazz
Pharmaceuticals shall reimburse GSK for the reasonable cost of any assistance provided, including direct costs for the time of internal GSK employees. 
 2.4
Transfer of Compound and Other Purchased Assets. Within ninety (90) days after the Closing Date (the “Asset Transfer Period”) (which period may be extended by the mutual agreement of the Parties), GSK will transfer to Jazz
Pharmaceuticals, at no additional cost to Jazz Pharmaceuticals, the quantities of GW273293 and other Compounds identified in Schedule 1.1.35(c). Jazz Pharmaceuticals acknowledges that GSK and its Affiliates [ * ] as permitted by this
Agreement, certain [ * ] GW273293 [ * ] in its [ * ], pursuant to [ * ] under Section 6.1. 
 2.5 Acknowledgement of Jazz
Pharmaceuticals Regarding Purchased Assets. Jazz Pharmaceuticals acknowledges that GSK has not [ * ] GW273293 [ * ], and that, as a result, the [ * ] contained in the [ * ] may be [ * ]. Jazz Pharmaceuticals
acknowledges that it is purchasing the Purchased Assets with this knowledge and with the understanding that successful development of GW273293 or the other Compounds will require significant efforts and expense of Jazz Pharmaceuticals. In addition,
Jazz Pharmaceuticals acknowledges that the quantities of GW273293 and other Compounds identified in Schedule 1.1.35(c) transferred to Jazz Pharmaceuticals may not be suitable in their current condition for use in human clinical trials, and that Jazz
Pharmaceuticals may need to conduct additional testing, without the assistance of GSK, on such quantities prior to any use in human clinical trials. 
 2.6
Non-Exclusive License Grant. Subject to the terms and conditions of this Agreement, effective as of the Closing Date, GSK grants Jazz Pharmaceuticals a worldwide, perpetual, royalty-free, non-exclusive license under the Licensed GSK Patents
solely for the purpose of exploiting the rights granted under the Patents and developing and commercializing a Product; provided, however, that, pursuant to Sections 3.3 and 3.5, Jazz Pharmaceuticals shall be obligated to pay milestones and
Additional Consideration Payments on Net Sales of Products for the indications covered by the Licensed GSK Patents. Such license granted hereunder shall be sublicensable by Jazz Pharmaceuticals in connection with activities relating to the
development and commercialization of Products and Compounds. Additionally, should Jazz Pharmaceuticals require a license under any GSK patent relating to the composition of matter or method of manufacturing sodium channel antagonist compounds or
other GSK patents that would block Jazz Pharmaceuticals from making and selling the Compounds as described in the Patents, GSK shall grant Jazz Pharmaceuticals a non-exclusive, royalty-free license under such GSK patents, to the extent GSK has the
right to grant such license at the time of Jazz Pharmaceutical’s request. 
 ARTICLE 3—PURCHASE PRICE; MILESTONE PAYMENTS AND ADDITIONAL
CONSIDERATION 
 3.1 Purchase Price. In consideration of GSK’s assignment and transfer of the Purchased Assets to Jazz Pharmaceuticals
pursuant to Section 2.1, Jazz Pharmaceuticals will pay a total of Two Million U.S. Dollars (U.S. $2,000,000) (the “Purchase Price”) on the Closing Date as follows: One Million U.S. Dollars (U.S. $1,000,000) to GGL, and One Million
U.S. Dollars (U.S. $1,000,000) to SB. Of the Purchase Price, $50,000 is paid in consideration of the transfer to 

  

 8 
 [ * ]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 
Jazz Pharmaceuticals of the quantities of GW273293 and other Compounds identified in Schedule 1.1.35(c), which Jazz Pharmaceuticals, may use for research and
development, including clinical activities. 
 3.2 Manner of Payment of Purchase Price. On the Closing Date, Jazz Pharmaceuticals will pay the
Purchase Price to GGL and SB as set forth in Section 3.1 by electronic wire transfer into accounts that have been designated by GGL and SB in writing at least two (2) Business Days prior to the Closing Date. 
 3.3 Milestone Payments. As further consideration for the assignment and transfer of the Purchased Assets pursuant to Section 2.1, Jazz Pharmaceuticals shall
pay GGL and SB the following non-refundable, non-creditable, irrevocable amounts (each, a “Milestone Payment”) within ten (10) days after the first achievement by or on behalf of Jazz Pharmaceuticals, its Affiliates or sublicensees of
the corresponding events set forth below (each, a “Milestone”) for the first Product to reach such Milestone, regardless whether the development, promotion, or marketing of such Product is discontinued at any time after the achievement of
such Milestone: 
  

			
	 PRE-COMMERCIAL MILESTONES
	    	 MILESTONE PAYMENT

	 1. First patient enrolled in the first Phase I Clinical Trial for a Product anywhere in the Territory, for the first Product to reach this
Milestone
	    	 (a) U.S. $1,500,000 to GGL,
 and (b) U.S. $1,500,000 to SB

		
	 2. First patient enrolled in the first Phase II Clinical Trial for a Product anywhere in the Territory, for the first Product to reach this
Milestone
	    	 (a) U.S. $2,500,000 to GGL,
 and (b) U.S. $2,500,000 to
SB

		
	 3. First patient enrolled in the first Phase III Clinical Trial for a Product anywhere in the Territory, for the first Product to reach
this Milestone
	    	(a) U.S. $[ * ] and (b) U.S. $[ * ]
		
	 4. Filing of the first MAA for a Product in the U.S. for the first indication, for the first Product to reach this
Milestone
	    	(a) U.S. $[ * ] and (b) U.S. $[ * ]
		
	 5. Filing of the first MAA (or first supplement or amendment to an MAA) requesting approval to market a Product for each additional indication
for a Product in the U.S. or filing of the first MAA for a second Product for indications other than those approved for a first Product
	    	(a) U.S. $[ * ] and (b) U.S. $[ * ]
		
	 6. Filing of the first MAA for Marketing Approval for a Product in any country in the EU (or the first centralized EU filing requesting
approval to market a Product)
	    	(a) U.S. $[ * ] and (b) U.S. $[ * ]
		
	 7. Filing of the first MAA for a Product in any country outside the U.S. and the EU, for the first Product to reach such
Milestone
	    	(a) U.S. $[ * ] and (b) U.S. $[ * ]

  

			
	 COMMERCIAL MILESTONES
	    	 MILESTONE PAYMENT

	 1. Receipt of the first Marketing Approval for a Product in the U.S.
	    	(a) U.S. $[ * ] and (b) U.S. $[ * ]
		
	 2. Receipt of the first U.S. Marketing Approval for each additional indication for any Product to receive approval for such indication
(including receipt of the first approval for any additional Product for indications other than those approved for the first Product)
	    	(a) U.S. $[ * ] and (b) U.S. $[ * ]

  

 9 
 [ * ]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

			
	 COMMERCIAL MILESTONES
	  	 MILESTONE PAYMENT

	 3. Receipt of the first Marketing Approval for a Product in any country in EU, for the first Product to achieve such Milestone
	  	(a) U.S. $[ * ] and (b) U.S. $[ * ]
		
	 4. Receipt of the first Marketing Approval for a Product in any country outside U.S. or EU, for the first Product to achieve such
Milestone
	  	(a) U.S. $[ * ] and (b) U.S. $[ * ]
		
	 5. Worldwide Gross Sales of Product first exceed US $300,000,000 in any twelve month period
	  	(a) U.S. $[ * ] and (b) U.S. $[ * ]
		
	 6. Worldwide Gross Sales of Product first exceed U.S. $500,000,000 in any twelve month period
	  	(a) U.S. $[ * ] and (b) $[ * ]        
		
	 7. Worldwide Gross Sales of Product first exceed U.S. $700,000,000 in any twelve month period
	  	(a) U.S. $[ * ] and (b) U.S. $[ * ]

 3.4 Notes on Milestone Payments. 
 (a) Each Milestone Payment shall be made only once regardless of how many times such Milestones are achieved for each Product, except for Pre-Commercial
Milestone number 5 and Commercial Milestone number 2 above which may be paid more than once (but only once for each [ * ]). No payment shall be owed for a Milestone which is not reached (except that, upon achievement of a Milestone for a
particular Product, any previous Milestone for that Product for which payment would have been due hereunder but was not yet made shall be deemed achieved and payment therefore shall be made), if such a payment was due under the terms hereof.

 (b) In the event that more than one Milestone is achieved with respect to the same Product at one time, then all applicable payments under
Section 3.3 shall be made. 
 (c) For purposes of Milestone payments, an “indication” means [ * ]. 
 (d) For purposes of [ * ] in the event federal governmental pricing approval is required to commercialize the Product in the U.S., then the
Milestone Payment for [ * ] shall not become due until the earlier of (i) [ * ] or (ii) [ * ] of Marketing Approval. 
 3.5
Additional Consideration Payments. As further consideration for the assignment and transfer of the Purchased Assets pursuant to Section 2.1, Jazz Pharmaceuticals will pay GGL and SB the following percentage (each an “Additional
Consideration Payment”) on Net Sales of Product in the Territory in each calendar year: 
 (a) with respect to Net Sales of Product
(other than Combination Products) in countries of the Territory as to which payments are due, in each calendar year: 
 (i) [ * ]
percent ([ * ]%) of annual Net Sales of Product up to and including [ * ] U.S. Dollars (U.S. $[ * ]) in such calendar year; and 
 (ii) [ * ] percent ([ * ]%) of annual Net Sales of Product in excess of [ * ] U.S. Dollars (U.S. $[ * ]) in such calendar year. 
 (b) After calculating the total Additional Consideration Payments due under Section 3.5(a) for all Net Sales in the Territory, Jazz Pharmaceuticals shall determine the 

  

 10 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 
amount of Net Sales in the U.S. and shall pay SB [ * ] percent ([ * ]%) or [ * ] percent ([ * ]%) of such Net Sales in the U.S.,
as appropriate, at the Additional Consideration Payment level required by Section 3.5(a). After calculating the total Additional Consideration Payments due under Section 3.5(a) for all Net Sales in the Territory, Jazz Pharmaceuticals shall
determine the amount of Net Sales in Europe and the ROW and shall pay GGL [ * ] percent ([ * ]%) or [ * ] percent ([ * ]%) of such Net Sales in Europe and the ROW, as appropriate, at the Additional Consideration Payment
level required by Section 3.5(a). In no event will any calculations under this paragraph result in a larger payment by Jazz Pharmaceuticals than would have been made had the entire payment been made to one entity. Jazz Pharmaceuticals will use
its Diligent Efforts to divide the Additional Consideration Payments as described above. If GSK believes that the division of the payment was not done correctly, GSK will, itself, reapportion the payments between the GSK entities and will not have
any recourse to Jazz Pharmaceuticals or request any audits as to the allocation between the GSK entities, and Jazz Pharmaceuticals will have no liability to GSK with respect to any division of the payments as described above. 
 (c) With respect to Net Sales of Combination Products in the Territory in each reporting period in each country: 
 (i) if and to the extent all therapeutically active agents comprising the Combination Product are marketed and sold separately in such country in
commercially relevant quantities in such Payment Period (as defined in Section 4.1) and the Gross Selling Price for each agent can be separately determined for such Payment Period, Net Sales of each Combination Product for determining the
Additional Consideration Payment payable with respect to such Combination Product for such country shall be calculated by multiplying the Net Sales of the Combination Product by A divided by the sum of A plus B (A/(A+B)), in which A is the Gross
Selling Price of the single therapeutically active agent Product contained in the Combination Product sold in such country during such Payment Period and B is the Gross Selling Price of the other single therapeutically active agent(s) contained in
the Combination Product sold in such country during such Payment Period. All Gross Selling Prices of the therapeutically active ingredients in the Combination Product shall be calculated as the average Gross Selling Price of the therapeutically
active ingredients in such Combination Products during the applicable Payment Period for which the Net Sales are being calculated. 
 (ii) In
the event that (a) separate sales, in commercially relevant quantities, in a particular country of the other therapeutically active agent (not the Product) comprising a single compound as a therapeutically active ingredient are made during the
Payment Period in which the sale was made or if the Gross Selling Price for such other therapeutically active agent (not the Product) can be determined for a Payment Period, but (b) there are no such separate sales of the Product as the sole
therapeutically active agent or such separate sales of the Product cannot be determined for such Payment Period, then the Net Sales of the Combination Product in such country for determining the Additional Consideration Payment payable with respect
to such Combination Product for such country for such period shall be calculated by multiplying Net Sales of such Combination Product in such country by the number one (1) minus the result of 

  

 11 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 
dividing X over Y (1—(X/Y)), in which X is the Gross Selling Price of the therapeutically active ingredient that is not a Product sold separately in
commercially reasonable quantities during the Payment Period in question and Y is the Gross Selling Price of the Combination Product sold in the Payment Period in question in such country. 
 (iii) If neither of the single therapeutically active agent components of the Combination Product is sold separately in commercially relevant quantities
in a country during a particular Payment Period, then the Additional Consideration Payment payable on such Combination Product in such country for such period will be [ * ] percent ([ * ]%) of the Additional Consideration Payment that
would be due on a Product that is not a Combination Product. 
 (d) Any Additional Consideration Payment due on Combination Products shall be
paid to SB for Net Sales of Combination Products in the U.S. and to GGL for Net Sales of Combination Products in the ROW. After determining the total Additional Consideration Payments due on Combination Products in accordance with
Section 3.5(c) above, Jazz Pharmaceuticals shall determine the Additional Consideration Payments due on Net Sales in the U.S. and in ROW, respectively, and shall pay such amounts to SB and GGL, respectively. 
 3.6 Starting Date of Additional Consideration Payment Obligations. The obligation of Jazz Pharmaceuticals to pay Additional Consideration Payments to GGL and SB
at the rates specified in Section 3.5 will become effective on a country by country basis on the date of the First Commercial Sale of a Product in such country. 
 3.7 Termination of Additional Consideration Payment Obligations. Additional Consideration Payments will be payable on Net Sales of Products in the U.S. until the expiration of the last-to-expire Valid Claim in
the Patents in force in the U.S. Additional Consideration Payments will be payable on Net Sales of Products in all countries of Europe until the expiration of the last-to-expire Valid Claim in the Patents in force in the last country in Europe in
which such Valid Claim is in force. Additional Consideration Payments will be payable on Net Sales of Products in all countries in the ROW until the expiration of the last-to-expire Valid Claim in the Patents in force in the last country in the ROW
in which such Valid Claim is in force. Additional Consideration on Net Sales of Products in Europe and the ROW is being paid in this manner as an administrative convenience to the Parties as a result of the difficulty in allocating value for each of
the Patents in Europe and the ROW. 
 3.8 Transfer and Other Taxes. Jazz Pharmaceuticals will be responsible for and will pay all foreign, federal,
state and local taxes payable in connection with the acquisition and transfer of the Purchased Assets to Jazz Pharmaceuticals by GSK. GSK will be responsible for and will pay all foreign, federal, state and local taxes payable on any income or gain
resulting from the sale of the Purchased Assets to Jazz Pharmaceuticals. Notwithstanding the foregoing, Jazz Pharmaceuticals shall not be required to pay (i) any VAT in connection with the transfer of the Purchased Assets, or (ii) any tax
as a result of the separate payment to SB pursuant to Sections 3.3 or 3.5 that it would not have been required to pay if making only one payment to GGL. In the event that Jazz Pharmaceuticals is required to withhold and remit any tax to the revenue
authorities in any country in the Territory regarding the Purchase Price, any Milestone payment or any Additional Consideration Payments payable to GGL or SB due to the laws of such country, such amount shall be withheld by Jazz Pharmaceuticals, and
Jazz Pharmaceuticals shall notify GSK and promptly furnish GSK with copies of any documentation evidencing such withholding. 
  

 12 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 ARTICLE 4—MANNER OF PAYMENTS; REPORTS; DILIGENCE 
 4.1 Manner of Additional Consideration Payments. 
 (a) Jazz Pharmaceuticals will deliver to GSK within sixty (60) days following the end of each
“Payment Period”, meaning a calendar quarter ending on March 31st, June 30th, September 30th or December 31st, the Additional Consideration Payment
Statements (as defined in Section 4.2), along with Jazz Pharmaceuticals’ payments to GGL and SB of any Additional Consideration Payment due and payable to GGL and SB for such Payment Period. 
 (b) Each Additional Consideration Payment will be computed and paid in U.S. Dollars. Monetary conversion calculations from the currency of a foreign
country in which a Product is sold into U.S. Dollars will be made on a quarterly basis on the last day of each applicable calendar quarter using the exchange rate reported on the last Business Day of such calendar quarter in the Wall Street Journal,
eastern edition. 
 (c) Whenever any Additional Consideration Payment is due on a day that is not a Business Day, such payment will be made on
the immediately succeeding Business Day. 
 (d) In the event that any payment due hereunder is not made when due, the payment shall accrue
interest from that date due at the rate of [ * ] percent ([ * ]%) per month, or the maximum rate allowed by law, whichever is less, and shall be calculated based on the number of days that the payment is delinquent. The payment of
such interest shall not limit GSK from exercising any other rights it may have as a consequence of the lateness of any payment. 
 4.2 Additional
Consideration Payment Statements. Each Additional Consideration Payment required hereunder will be accompanied by a report (“Additional Consideration Payment Statement”) for the preceding Payment Period containing the following
information: 
 (a) itemized accounting of the total Net Sales for Product during the applicable Payment Period in each country of sale in
sufficient detail to permit confirmation of the accuracy of the Additional Consideration Payment; 
 (b) adjustments and calculation of Net
Sales for the applicable Payment Period in each country of sale; and 
 (c) total Net Sales in U.S. dollars, together with the exchange rates
used for conversion. 
 If no payment is due to GGL or SB for any Payment Period, the Additional Consideration Payment Statement will so state. All
Additional Consideration Payment Statements will be considered Jazz Pharmaceuticals’ Confidential Information under this Agreement, but GSK may disclose such Confidential Information in accordance with Section 11.2 or Section 11.3.

 4.3 Additional Consideration Payment Post-Termination Report. Jazz Pharmaceuticals will make a written report to GSK within thirty (30) days
after the date of any termination of 

  

 13 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 
Additional Consideration Payment obligations under this Agreement, stating in such report the number, description and Net Sales of Products sold or otherwise
disposed of and on which an Additional Consideration Payment is payable hereunder that was not previously reported to GSK. 
 4.4 Audit. Upon the
written request of GSK (but not more frequently than [ * ]), GSK will have the right, upon thirty (30) days advance notice to Jazz Pharmaceuticals and at a mutually agreeable time, to have an independent certified public accountant or
like individual reasonably acceptable to Jazz Pharmaceuticals (the “Auditor”) inspect, during normal business hours, Jazz Pharmaceuticals’ directly applicable records for the preceding two (2) years for the purpose of determining
the accuracy of Additional Consideration Payment Statements and the associated Additional Consideration Payment made to GGL and SB pursuant to this Agreement. The results of any such examination shall be made available to Jazz Pharmaceuticals. In
the event the Auditor concludes that there was an underpayment of the total Additional Consideration Payment to GGL and SB together, the underpayment will be paid by Jazz Pharmaceuticals to GGL or SB or both, as applicable (but subject to the
provisions of Section 3.5(b) concerning allocations between GGL and SB), within sixty (60) Business Days after the date Jazz Pharmaceuticals receives such Auditor’s written report; provided, however, if Jazz Pharmaceuticals desires to
contest such audit results, Jazz Pharmaceuticals may do so by submitting the results of the audit to arbitration through JAMS New York or San Francisco offices within thirty (30) days after the receipt of such audit, and the arbitration shall
be final and binding on GSK and Jazz Pharmaceuticals. Pending the results of such arbitration, Jazz Pharmaceuticals shall be entitled to withhold any disputed amounts claimed by GSK as a result of the audit. In the event the Auditor concludes that
there was an overpayment of Additional Consideration Payment to GGL or SB or both, as applicable, the overpayment will be credited toward the next Additional Consideration Payment to be paid by Jazz Pharmaceuticals to GGL or SB or both, as
applicable, under this Agreement until fully credited; provided, however, that in the event no further Additional Consideration Payment will become due under this Agreement, such overpayment will be paid by GGL or SB or both, as applicable,
to Jazz Pharmaceuticals within sixty (60) Business Days after the date GSK receives such Auditor’s written report. If the underpayment of Additional Consideration is greater than [ * ] percent ([ * ]%) of the Additional
Consideration Payment determined by the Auditor to be payable to GSK, the reasonable fees and expenses charged by the Auditor will be paid by Jazz Pharmaceuticals; otherwise GSK will pay the reasonable fees and expenses charged by such Auditor. The
Auditor will report to GSK only its conclusions as to whether Jazz Pharmaceuticals is in compliance with its Additional Consideration Payment obligations and the amount of any underpayment or overpayment, and such report and the conclusions
contained therein will constitute Jazz Pharmaceuticals’ Confidential Information in accordance with Section 11.1. 
 4.5 Diligence.

 (a) Product Development Diligence. Jazz Pharmaceuticals shall exercise its Diligent Efforts to develop a Product for marketing and
sale in the Territory. In connection therewith, Jazz Pharmaceuticals shall use its Diligent Efforts to achieve the development objectives set forth below by the corresponding times set forth below: 
 (i) enroll the first patient in a Phase I Clinical Trial for a Product not later than thirteen (13) months after the Closing Date; 
 (ii) [ * ]; and 
 (iii) file an MAA for
a Product in the U.S. not later than twelve (12) months after completion of all Phase III Clinical Trials. 
  

 14 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 (b) Commercialization Diligence. Jazz Pharmaceuticals shall devote its Diligent Efforts to launch
a Product in each of the Major Market Countries in which Marketing Approval of a Product is granted within twelve (12) months after the date on which such Marketing Approval is granted, subject to, with respect to each Major Market Country, the
availability of commercially acceptable pricing, competitive conditions, product life cycle and other customary commercial conditions. 
 (c)
Patent Diligence. Jazz Pharmaceuticals shall devote its Diligent Efforts to prosecute, maintain, defend and enforce, in the Major Market Countries, Patents in the Major Market Countries that have been transferred to Jazz Pharmaceuticals in
accordance with Section 2.1. 
 (d) Failure to Achieve Objectives. Failure to achieve any of the development objectives described in
Section 4.5(a) or the commercial objective set forth in Section 4.5(b) at the times set forth therein shall not be a breach of this Agreement and shall not result in the availability of the remedies set forth in Section 9.2; provided,
however, that the failure of Jazz Pharmaceuticals to exercise Diligent Efforts to achieve the development and commercial objectives set forth above shall constitute material breach of this Agreement and, upon such breach, GSK, in its discretion, may
terminate the Agreement in accordance with Section 9.2. Any time period described in Section 4.5(a) or (b) shall be extended for the same period of time as any delay caused by GSK in transferring the Purchased Assets to Jazz
Pharmaceuticals or any delay which was outside the control of Jazz Pharmaceuticals. 
 4.6 Cessation or Suspension of Development Efforts. If Jazz
Pharmaceuticals ceases or suspends development efforts for all of GW273293 and the other Products covered by the Patents (such that efforts have been suspended with respect to all of the Compounds) for a period of fourteen (14) successive months,
such cessation or suspension of development efforts shall constitute a failure of Diligent Efforts by Jazz Pharmaceuticals and a material breach of this Agreement. Upon such material breach, GSK, in its discretion, may terminate this Agreement in
accordance with Section 9.2. 
 4.7 Termination of Development or Commercialization by Jazz Pharmaceuticals. 
 (a) If Jazz Pharmaceuticals determines to cease Diligent Efforts (alone or with a Third Party) to develop and commercialize all Products prior to
enrolling a patient in the first Phase II Clinical Trial for the first Product, Jazz Pharmaceuticals shall so notify GSK in writing. In such event, GSK shall have a period of sixty (60) days after the date of Jazz Pharmaceuticals’ notice to
reacquire the rights to all the Products in their then-current condition, for a price equal to all Milestone Payments paid by Jazz Pharmaceuticals to GSK hereunder with respect to the Products prior to the reacquisition by GSK. If GSK reacquires the
Products under this Section 4.7(a), Jazz Pharmaceuticals shall have no obligation to provide GSK with any data generated by Jazz Pharmaceuticals regarding the Products. 
 (b) If Jazz Pharmaceuticals determines to cease Diligent Efforts (alone or with a Third Party) to develop and commercialize all Products at any time after enrolling a patient in the first Phase II Clinical Trial for
the first Product, Jazz Pharmaceuticals shall so notify GSK in writing. In such event, GSK shall have a period of sixty (60) days after the date of Jazz Pharmaceuticals’ notice to reacquire the rights to the Products in their then-current
condition, for a price equal to the sum of (a) all amounts paid by Jazz Pharmaceuticals to GSK hereunder with respect to the Products, plus (b) all amounts expended by Jazz Pharmaceuticals to develop and commercialize the Products prior to the
reacquisition by GSK. In its notice to GSK, Jazz Pharmaceuticals shall advise GSK of the total amount it has expended to develop and commercialize the Products. If GSK reacquires the Products under this Section 4.7(b), Jazz Pharmaceuticals shall
provide GSK with all data generated by Jazz Pharmaceuticals regarding the Products. 
 Upon receipt of notice from Jazz Pharmaceuticals under
Section 4.7(a) or 4.7(b), GSK shall have the option, exercisable by written notice to Jazz Pharmaceuticals given within sixty (60) days after Jazz Pharmaceuticals’ notice, to reacquire the Product and all of Jazz Pharmaceuticals’
rights to the Product. In the event that GSK exercises such option, the Parties shall work together 

  

 15 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 
diligently to complete such reacquisition within the sixty (60) days following GSK’s exercise of such option, and Jazz Pharmaceuticals shall provide
assistance to GSK, on a level commensurate to the assistance provided by GSK to Jazz Pharmaceuticals pursuant to Section 2.2 and 2.3, to transfer and assign the Purchased Assets to GSK. If the option is not exercised within the sixty (60) day
period described above, it will terminate, and GSK shall have no further right to reacquire any Products. 
 4.8 [ * ] Reports. On a [ *
] basis until [ * ], Jazz Pharmaceuticals shall submit summary written reports to GSK describing Jazz Pharmaceuticals’ [ * ]. 
 ARTICLE 5—CLOSING 
 5.1 Closing Date; Time and Place of Closing. The transfer of title to the Purchased Assets and the
closing of the transactions contemplated by this Agreement will occur on October 4, 2004 (the “Closing Date”) at or before the Time of Closing at 3180 Porter Drive, Palo Alto, California, U.S., or at such other place as may be agreed
upon in writing by the Parties hereto. 
 5.2 Closing Arrangements. 
 (a) GSK’s Delivery of Closing Documents. At the Time of Closing on the Closing Date, GSK will execute and deliver to Jazz Pharmaceuticals: 
 (i) a Bill of Sale in the form of Schedule A attached hereto and incorporated herein, duly executed by GSK; 
 (ii) an Assignment of Patent Rights in the form of Schedule B attached hereto and incorporated herein, duly executed by GSK; and 
 (iii) this Agreement, duly executed by GSK. 
 In addition, at the Time of Closing, GSK will pay and satisfy the [ * ] as provided in Section 6.1. 
 (b) Jazz
Pharmaceuticals’ Payment of Purchase Price and Delivery of Closing Documents: At the Time of Closing on the Closing Date, Jazz Pharmaceuticals will: 
 (i) pay and satisfy the Purchase Price as provided in Section 3.1, payable via wire transfer to accounts that have been designated by GGL and SB at least two (2) Business Days prior to the Closing Date; and

 (ii) deliver this Agreement, duly executed by Jazz Pharmaceuticals. 
 5.3 Conditions of Obligations of Jazz Pharmaceuticals. The obligations of Jazz Pharmaceuticals to effect the transactions contemplated hereby are also subject to the satisfaction of the following conditions,
unless waived in writing by Jazz Pharmaceuticals on or prior to the Closing Date: 
 (a) The representations and warranties of GSK set forth
in this Agreement shall be true and correct as of the Time of Closing; 
  

 16 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 (b) GSK shall have performed all conditions, obligations and covenants required to be performed by it
under this Agreement prior to the Time of Closing; 
 (c) Jazz Pharmaceuticals shall have received duly executed copies of all Third Party
consents, approvals and assignments contemplated by this Agreement and necessary to transfer all of GSK’s interest in the Purchased Assets, in form and substance reasonably satisfactory to Jazz Pharmaceuticals; and 
 (d) Subject to Section 2.5, there shall have been no material change in the Compounds or the Purchased Assets. 
 5.4 Conditions of Obligations of GSK. The obligations of GSK to effect the transactions contemplated hereby are also subject to the satisfaction of the following
conditions, unless waived in writing by GSK on or prior to the Closing Date: 
 (a) The representations and warranties of Jazz Pharmaceuticals
set forth in this Agreement shall be true and correct as of the Time of Closing; 
 (b) Jazz Pharmaceuticals shall have performed all
conditions, obligations and covenants required to be performed by it under this Agreement prior to the Time of Closing; and 
 (c) There shall
have been no material adverse change to the business or financial condition of Jazz Pharmaceuticals. 
 5.5 Transfer after Closing Date. While title
to the Purchased Assets will pass to Jazz Pharmaceuticals on the Closing Date, the physical transfer of the Purchased Assets will take place during the Asset Transfer Period. In the event that Jazz Pharmaceuticals seeks additional data from GSK
pertaining to the Purchased Assets, Jazz Pharmaceuticals may, during the Asset Transfer Period, make a specific request of GSK for copies of such additional data. GSK will endeavor to locate such data, where available, within a reasonable period of
time. If, despite GSK’s reasonable endeavors it cannot locate such additional data, GSK will promptly notify Jazz Pharmaceuticals in writing. GSK will be responsible for the physical transfer of the Purchased Assets (including compliance and
costs associated with any export control laws or regulations and any required governmental authorizations) to Jazz Pharmaceuticals’ chosen destination during the Asset Transfer Period. Risk of loss of the Purchased Assets will pass to Jazz
Pharmaceuticals upon receipt of such by Jazz Pharmaceuticals. 
 5.6 Expenses for Transfer of the Purchased Assets. Except as provided in this
Agreement, after the Time of Closing on the Closing Date, Jazz Pharmaceuticals will be responsible for all costs related to the recordation and perfection of the assignment of the Purchased Assets and Jazz Pharmaceuticals will bear all costs and
fees imposed by governmental authorities related thereto and all postage costs. Except as otherwise expressly provided herein, all other costs, fees and expenses arising from the transfer of the Purchased Assets to Jazz Pharmaceuticals as
contemplated by this Agreement will be paid by the Party incurring such costs and expenses. 
  

 17 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 ARTICLE 6 — LICENSE 
 6.1 Grantback License to GSK. Jazz Pharmaceuticals hereby grants to GSK for One U.S. Dollar (U.S. $1.00) (“License Fee”) a fully paid-up and royalty-free, non-exclusive, worldwide, perpetual and
irrevocable license under the Purchased Assets for GSK’s internal research purposes only, excluding clinical research (“Grantback License”). In accordance with Section 6.3, until the expiration of the last to expire Valid Claim in the
Patents in each of the U.S., Europe and ROW, respectively, GSK shall have no right under the Grantback License to develop, market, sell or promote any Compound in the U.S., Europe or the ROW, respectively. Prior to the expiration of the last Valid
Claim in the Patents in the U.S., Europe and the ROW, respectively, should GSK wish to develop, market, sell or promote a Compound other than GW273293 in the U.S., Europe or the ROW where a Valid Claim exists, GSK shall notify Jazz Pharmaceuticals,
and Jazz Pharmaceuticals and GSK shall negotiate, for a period of up to 90 days, the grant by Jazz Pharmaceuticals to GSK of a royalty-bearing license to permit GSK to develop, market, sell and promote such Compound, but Jazz Pharmaceuticals will
have no obligation to grant such a license. 
 6.2 Sublicense. GSK will have the right to grant sublicenses under the Grantback License granted
under Section 6.1 to its Affiliates and Third Parties that enter into bona fide research collaborations with GSK; provided that, in each instance (a) such sublicense shall be used solely for internal research, excluding clinical research, purposes
only and (b) any such sublicensee shall be bound by similar terms of confidentiality and non-use at least equivalent in scope to those set forth in Article 11. 
 6.3 Development or Commercialization by GSK of Products. GSK will not develop, commercialize or sell any Product in the U.S. until the expiration of the last to expire Valid Claim in the Patents in force in the U.S. GSK will not
commercialize or sell any Product in any country in Europe until the expiration of the last to expire Valid Claim in the Patents in the last country in Europe in which such Valid Claim was in force. GSK will not commercialize or sell any Product in
any country in the ROW until the expiration of the last to expire Valid Claim in the Patents in the last country in the ROW in which such Valid Claim was in force. This provision shall not prevent GSK from researching any Compound covered by the
Patents in accordance with the license granted to GSK in Section 6.1. 
 ARTICLE 7—REPRESENTATIONS AND WARRANTIES 
 7.1 Representations and Warranties of Jazz Pharmaceuticals. Jazz Pharmaceuticals hereby represents and warrants to GSK and acknowledges that GSK is relying on
such representations and warranties in connection with the transactions contemplated by this Agreement that, as of the Closing Date: 
 (a) Incorporation, Organization and Qualification of Jazz Pharmaceuticals. Jazz Pharmaceuticals is a corporation duly incorporated, validly existing and in good standing under the laws of the jurisdiction of its incorporation, and
has the corporate power to own or lease its property and to carry on its business as now being conducted by it and to execute, deliver and perform this Agreement. Jazz Pharmaceuticals is duly qualified to do business as a foreign corporation and is
in good standing in every jurisdiction where the nature of the business conducted by it makes such qualification necessary, except in such jurisdictions where the failure to so qualify does not in the aggregate have a material adverse effect on its
respective businesses taken as a whole. 
 (b) Corporate Action. This Agreement, and any other agreements and
instruments executed in connection herewith and therewith are the valid and binding obligations of Jazz Pharmaceuticals, enforceable in accordance with their respective terms, subject to bankruptcy, insolvency or similar laws of general application
affecting the enforcement of rights of creditors, and subject to equitable principles limiting rights to specific performance or other equitable remedies and subject to the effect of federal and state securities laws on the enforceability of
indemnification provisions relating to liabilities arising under such laws. The execution, delivery and performance of this Agreement and any other agreement and instruments executed in connection herewith and therewith have been duly authorized by
all necessary corporate action. 
 (c) Governmental Approvals. No authorization, consent, approval, license, exemption
of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable laws, rules or regulations presently in effect, is or will be necessary for, or
in connection with, the offer, issuance, sale, execution or delivery by Jazz Pharmaceuticals of the Agreement or any other agreement or instrument executed in connection herewith, or for the performance by it of its obligations under this Agreement.

  

 18 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 (d) Sufficient Funds. Jazz Pharmaceuticals represents that it has, or will have at the Time of
Closing, sufficient funds to fulfill its obligation to pay the Purchase Price and Milestone Payments to GSK. 
 (e) Compliance With
Law. Jazz Pharmaceuticals has complied and is in compliance with all applicable foreign, federal, state and local laws, statutes, licensing requirements, rules and regulations, and judicial or administrative decisions applicable to Jazz
Pharmaceuticals in connection with the transaction contemplated hereby. 
 7.2 Representations and Warranties of GSK. GSK hereby represents and
warrants to Jazz Pharmaceuticals and acknowledges that Jazz Pharmaceuticals is relying on such representations and warranties in connection with the transactions contemplated by this Agreement that, as of the Closing Date: 
 (a) Incorporation, Organization and Qualification of GSK. Each of GGL and SB is a corporation duly incorporated, validly existing and in good
standing under the law of the jurisdiction of its incorporation, and has the corporate power to own or lease its property and to carry on its business as now being conducted by it. Each of GGL and SB is duly qualified to do business as a foreign
corporation and is in good standing in every jurisdiction where the nature of the business conducted by it makes such qualification necessary, except in such jurisdictions where the failure to so qualify does not in the aggregate have a material
adverse effect on its respective businesses taken as a whole. 
 (b) Corporate Action. This Agreement, and any other agreements and
instruments executed in connection herewith and therewith are the valid and binding obligations of each of GSK, enforceable in accordance with their respective terms, subject to bankruptcy, insolvency or similar laws of general application affecting
the enforcement of rights of creditors, and subject to equitable principles limiting rights to specific performance or other equitable remedies. The execution, delivery and performance of this Agreement and any other agreement and instruments
executed in connection herewith and therewith have been duly authorized by all necessary corporate action. 
 (c) Governmental
Approvals. No authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable laws,
rules or regulations presently in effect, is or will be necessary for, or in connection with, the offer, issuance, sale, execution or delivery by GGL or SB of the Agreement or any other agreement or instrument executed in connection herewith, or for
the performance by it of it obligations under this Agreement. 
 (d) Title to Purchased Assets. 
 (i) GSK is the sole and exclusive owner of the Purchased Assets, and the Purchased Assets are free and clear of any and all liens, pledges, mortgages,
security interests, restrictions, and encumbrances. By virtue of the deliveries made at the Time of Closing, Jazz Pharmaceuticals will obtain good and marketable title to all of the Purchased Assets, free and clear of any and all liens, 

  

 19 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 
pledges, mortgages, security interests, restrictions and encumbrances. To GSK’s knowledge, no government funds, equipment, facilities, personnel or
other resources were used in connection with the discovery or development of the Purchased Assets. 
 (ii) None of GSK, GGL or SB has granted
and will not grant during the Term of this Agreement, any right to any Affiliate or Third Party which would conflict with the rights granted to Jazz Pharmaceuticals hereunder, and GSK will not take (or cause any other person or entity to take) any
action that will conflict with, contravene or otherwise limit or restrict the rights of Jazz Pharmaceuticals hereunder or the right of Jazz Pharmaceuticals to enjoy the benefits of this Agreement. 
 (iii) The Purchased Assets constitute all of the material assets used by GSK and its Affiliates in the development of GW273293 and the manufacturing
Know-how specifically relating to GW273293, other than manufacturing equipment. Except for the quantities of GW273293 duly retained by GSK pursuant to Section 2.4, neither GSK nor its Affiliates will have any supply of GW273293 at the
expiration of the Asset Transfer Period, nor is GSK or its Affiliates in the process of, or planning to, manufacture any additional amounts of GW273293, except for the purposes permitted by the [ * ]. 
 (iv) Schedule 1.1.29 lists all Patents related to the Compounds, or any formulation or process of manufacture or formulation specifically related to
GW273293, or use thereof in the Territory including any patent term extensions, supplementary protection certificates, registrations, extensions, reissues, reexaminations or divisionals thereof, and including any granted patents arising from the
pending applications. 
 (e) Litigation. No action, claim, suit, proceeding or investigation is pending in respect of the Purchased
Assets in the United States or Europe or, to GSK’s knowledge, anywhere else in the Territory. To GSK’s knowledge, no action, claim, suit, proceeding or investigation is threatened against GSK or its Affiliates in respect of the Purchased
Assets anywhere in the Territory. There is no judgment, decree, injunction, rule or order of any court, governmental department, commission agency, instrumentality or arbitrator or other similar ruling outstanding against GSK or its Affiliates
relating to the Purchased Assets. No action, claim, suit, proceeding or investigation is pending or threatened by GSK or its Affiliates, nor, to GSK’s knowledge, is there any basis for such, against any Third Party relating to the Purchased
Assets. 
 (f) No Existing Claims of Infringement. To the knowledge of GSK’s Corporate Intellectual Property Group, there are no
claims existing against GSK or its Affiliates asserting that the manufacture, use or sale of GW273293 infringes, constitutes contributory infringement, inducement to infringe or misappropriation of any patent rights, trade secret rights or other
intellectual property or proprietary rights of any Third Party. GSK hereby represents and warrants that GSK’s Corporate Intellectual Property group referenced in this Agreement is the only group within GSK that prosecutes and maintains patents.

 (g) Taxes; Maintenance Fees. All taxes imposed by the United States, any state, municipality, other local government or other
subdivision or instrumentality of the United 

  

 20 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 
States or the countries of EU that are due or payable by GSK or any of its Affiliates with respect to the Purchased Assets, and all interest and penalties
thereon, whether disputed or not, and that would result in the imposition of a lien, claim or encumbrance on any of the Purchased Assets, other than taxes that are not yet due and payable, have been paid in full, all tax returns required to be filed
in connection therewith with respect to the Purchased Assets have been accurately prepared and duly and timely filed in the United States and countries of the EU. To GSK’s knowledge, all taxes imposed by any other country or any state or other
government thereof, or any other taxing authority, that are due or payable by GSK or any of its Affiliates with respect to the Purchased Assets, and all interest and penalties thereon, whether disputed or not, and that would result in the imposition
of a lien, claim or encumbrance on any of the Purchased Assets, other than taxes that are not yet due and payable, have been paid in full, all tax returns required to be filed in connection therewith with respect to the Purchased Assets have been
accurately prepared and duly and timely filed. GSK is not delinquent in the payment of any foreign or domestic tax, assessment or governmental charge or deposits in the U.S. or the EU or, to GSK’s knowledge, in any other country that would
result in the imposition of a lien, claim or encumbrance on any of the Purchased Assets or against Jazz Pharmaceuticals, and neither GSK nor any of its Affiliates has a tax deficiency or claim outstanding, proposed or assessed against it, and, to
GSK’s knowledge, there is no basis for any such deficiency or claim, that would result in the imposition of any lien, claim or encumbrances on any of the Purchased Assets or against Jazz Pharmaceuticals. All maintenance fees and any other fees
for the Patents have been timely paid. 
 (h) Compliance With Law. To GSK’s knowledge, GSK and its Affiliates have complied and
are in compliance with all applicable foreign, federal, state and local laws, statutes, licensing requirements, rules and regulations, and judicial or administrative decisions applicable to their ownership and use of the Purchased Assets, including
without limitation all laws, rules and regulations regarding the development, clinical testing, manufacture, licensing, marketing, promotion, importation, exportation or other use of pharmaceutical products, except where such failure to do so would
not materially adversely affect, or reasonably be expected to so affect, any of the Purchased Assets or the ability of GSK to consummate the transactions contemplated herein. GSK and its Affiliates have been granted any and all licenses, permits
(temporary and otherwise), authorization and approvals from federal, state, local and foreign government regulatory bodies necessary to own and use the Purchased Assets, except where the failure to possess such license, permit, authorization or
approval would not have a materially adverse effect, or reasonably be expected to so affect, any of the Purchased Assets or the ability of GSK, GGL and SB have to consummate the transactions contemplated herein. 
 (i) Full Disclosure. This Agreement and the Schedules attached hereto, when taken as a whole, do not contain any untrue statement of a material
fact nor, to GSK’s knowledge, information and belief, omit to state a material fact necessary in order to make the statements contained herein or therein not misleading. 
 (j) Limitations. 
 (i) EXCEPT AS
EXPRESSLY SET FORTH IN THIS SECTION 7.2, THE COMPOUNDS AND PURCHASED ASSETS ARE PROVIDED “AS IS,” AND 

  

 21 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 
GSK MAKES NO REPRESENTATIONS OR WARRANTIES (WHETHER EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH RESPECT TO THE COMPOUNDS OR PURCHASED ASSETS, INCLUDING,
WITHOUT LIMITATION, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, INCLUDING USE IN CLINICAL TRIALS, OR FREEDOM FROM INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. JAZZ PHARMACEUTICALS ACKNOWLEDGES THAT
ALL CHARACTERISTICS OF THE COMPOUNDS ARE NOT FULLY UNDERSTOOD AND ANY USE THEREOF MAY INVOLVE RISKS OR DANGERS THAT ARE NOT KNOWN OR FULLY APPRECIATED. 
 (ii) NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT, JAZZ PHARMACEUTICALS WILL BE RESPONSIBLE FOR (AND GSK WILL HAVE NO RESPONSIBILITY FOR) ALL LIABILITIES ARISING SOLELY FROM ACTS OR OMISSIONS TO ACT BY JAZZ
PHARMACEUTICALS, ITS AFFILIATES OR SUBLICENSEES AFTER THE TIME OF CLOSING RELATED TO THE PURCHASED ASSETS OR THE USE BY JAZZ PHARMACEUTICALS, ITS AFFILIATES OR SUBLICENSEES OF THE PURCHASED ASSETS TO IDENTIFY, RESEARCH, DEVELOP, MANUFACTURE, MARKET,
PROMOTE, DISTRIBUTE, SELL OR IMPORT ANY PRODUCTS, EXCEPT WHERE SUCH LIABILITY, LOSS, DAMAGE, COST AND EXPENSE HAS BEEN INCURRED OR SUFFERED AS A RESULT OF A MATERIAL BREACH OF GSK’S REPRESENTATIONS, WARRANTIES OR OBLIGATIONS UNDER THIS
AGREEMENT OR BY GROSS NEGLIGENCE OR WILLFUL MISCONDUCT ON THE PART OF GSK. 
 (k) Any representation or warranty by GSK herein will also be
deemed to have been made by each of GGL and SB, individually as to itself, and the breach of any representation or warranty by any one of them will be deemed to be a breach by the others. 
 ARTICLE 8—LIABILITY AND INDEMNIFICATION 
 8.1
Indemnification by GSK. GSK will indemnify, defend and hold harmless Jazz Pharmaceuticals, its Affiliates, and each of their respective members, directors, officers, employees, advisors and agents (collectively, “Jazz Pharmaceuticals
Indemnitees”) from and against any and all suits, actions, damages, liabilities, claims (including death and bodily injury), demands, obligations, losses, fees, costs and expenses or money judgments (including reasonable attorneys’ fees)
(collectively, “Claims”) incurred by or rendered against any Jazz Pharmaceuticals Indemnitee which arise out of or in connection with: 
 (a) any Claims related to the Purchased Assets or against the Purchased Assets, in each case based upon events which occurred at or prior to the Time of Closing; or 
 (b) liabilities of GSK or its Affiliates to the extent related to the Purchased Assets and existing as of, or prior to, the Closing Date or based on
actions taken or omissions to act that occurred prior to the Time of Closing (including any infringement or misappropriation of Third Party patents or intellectual property); 
  

 22 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 (c) any breach or inaccuracy of any representation, warranty or covenant of GSK set forth in this
Agreement; or 
 (d) the negligence or willful misconduct of any GSK Indemnitees; 
 provided, however, that in each case GSK will not be obligated to indemnify any Jazz Pharmaceuticals Indemnitee with respect to, and to the extent of, any Claims for
which Jazz Pharmaceuticals is obligated to indemnify GSK pursuant to Section 8.2. 
 8.2 Indemnification by Jazz Pharmaceuticals. Jazz
Pharmaceuticals will indemnify and hold harmless GSK and its Affiliates and each of their directors, officers, employees, advisors and agents (collectively, the “GSK Indemnitees”) from and against any and all Claims incurred by or rendered
against any GSK Indemnitee which arise out of or in connection with: 
 (a) the development, manufacture, licensing, marketing, promotion,
importation, exportation, sale or other use of the Purchased Assets from and after the Time of Closing by or on behalf of any Jazz Pharmaceuticals Indemnitees of any Product or service or any product or material embodying or made through the use of
any part of the Purchased Assets; provided however, it is agreed by the Parties that such indemnification will not apply to the extent that any product or service arises from the exercise of the [ * ] by GSK, its Affiliates, agents [ *
]; 
 (b) any breach or inaccuracy of any representation, warranty or covenant made by Jazz Pharmaceuticals pursuant to this Agreement; or

 (c) the negligence or willful misconduct of any Jazz Pharmaceuticals Indemnitees; 
 provided, however, that in each case Jazz Pharmaceuticals will not be obligated to indemnify any GSK Indemnitees with respect to, and to the extent of, any Claims for
which GSK is obligated to indemnify Jazz Pharmaceuticals Indemnitees pursuant to Section 8.1. 
 8.3 Indemnification Process. No Party against
whom a claim of indemnity is made under this Agreement (the “Indemnifying Party”) will be liable unless the Party making such claim (the “Claimant Party”) (a) promptly notifies the Indemnifying Party in writing of such claim
upon becoming aware of the existence or threatened existence of any such claim giving rise to or which may give rise to a claim of indemnity (provided, however that the failure to provide written notice of such claim within a reasonable period of
time will not relieve the Indemnifying Party of any obligations hereunder, except to the extent that the Indemnifying Party is prejudiced by such failure), (b) permit the Indemnifying Party to assume direction and control of the defense of the
claim, and (c) cooperates in the defense of such claim. Notwithstanding the foregoing, the Indemnifying Party shall not enter into any settlement or compromise of any claims without the express written consent of the Claimant Party in each
instance where such settlement would include any admission of liability on the part of the Claimant Party, where the settlement would impose any material restriction on the conduct of the Claimant Party of any of its activities, or where the
settlement would not include an unconditional release of the Claimant Party from all liability for claims that are the subject matter of such claim. 
 8.4
Limitation on Indemnification. NEITHER JAZZ PHARMACEUTICALS AND ITS AFFILIATES NOR GSK AND ITS AFFILIATES WILL BE LIABLE HEREUNDER UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE REMEDIES FOR ANY INCIDENTAL OR
CONSEQUENTIAL DAMAGES OR LOST PROFITS. 
  

 23 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 ARTICLE 9—TERM AND TERMINATION 
 9.1 Term; Expiration. 
 (a) This Agreement shall become effective as of the Effective Date, and
GSK’s sale, transfer and assignment of its rights to the Purchased Assets to Jazz Pharmaceuticals, and the transfer of title to such Purchased Assets shall be accomplished on the Closing Date, subject to satisfaction of the conditions set forth
in Sections 5.3 and 5.4. As provided in Section 5.5, the physical transfer of the Purchased Assets will occur during the Asset Transfer Period. After the Closing Date, unless earlier terminated pursuant to Section 9.2, this Agreement shall
expire on expiration of the last-to-expire Valid Claim in the Patents anywhere in the Territory. 
 (b) The period from the Effective Date to
the expiration of the entire Agreement pursuant to this Section 9.1 shall be the “Term.” The end of the Term shall not terminate or affect the transfer of Patents pursuant to Section 2.1 or the license granted under
Section 2.6; and no Purchased Assets transferred to Jazz Pharmaceuticals hereunder shall be returned at the end of the Term. 
 9.2 Termination for
Cause. 
 (a) Material Breach. Either Party (the “Non-breaching Party”) may, without prejudice to any other
remedies available to it at law or in equity, terminate this Agreement in its entirety in the event the other Party (the “Breaching Party”) shall have committed a material breach, and such material breach shall have continued and/or
remained uncured for sixty (60) days after written notice thereof was provided to the Breaching Party by the Non-breaching Party. Any such termination shall become effective at the end of such sixty (60) day period, unless the Breaching
Party has cured any such material breach prior to the expiration of such sixty (60) day period. The sixty (60) day cure period provided for herein shall be extended for as long as a Breaching Party is making Diligent Efforts to cure such
material breach. The right of either Party to terminate this Agreement as provided in this Section 9.2 shall not be affected in any way by such Party’s waiver or failure to take action with respect to any previous default. 
 (b) Effect of Termination by Jazz Pharmaceuticals on GSK’s Material Breach. In the event Jazz Pharmaceuticals terminates this Agreement
pursuant to Section 9.2(a) as a result of an uncured material breach by GSK, (i) all rights granted to Jazz Pharmaceuticals hereunder will continue unaffected, including the license granted to Jazz Pharmaceuticals pursuant to
Section 2.6, (ii) no further payments will be due to GSK hereunder, (iii) Jazz Pharmaceuticals’ diligence obligations under Section 4.5 will terminate, and (iv) Section 6.3 will continue in accordance with its
terms. 
 (c) Effect of Termination by GSK on Jazz Pharmaceutical’s Material Breach. In the event GSK terminates this Agreement
pursuant to Section 9.2(a) as a result of an uncured material breach by Jazz Pharmaceuticals, (i) Jazz Pharmaceuticals shall cease all development and marketing of the Compounds or Products and immediately shall assign and transfer back to
GSK all rights to the Purchased Assets; and (ii) the license 

  

 24 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 
granted to Jazz Pharmaceuticals pursuant to Section 2.6 shall terminate. In consideration of the transfer of the Purchased Assets to it, GSK shall pay
Jazz a sum equal to the sum of all amounts previously paid by Jazz Pharmaceuticals to GSK hereunder, excluding the Purchase Price. In the event of such termination, the Parties will work together diligently to complete the reacquisition of the
Purchased Assets by GSK within ninety (90) days following GSK’s notice of termination and intent to reacquire the Purchased Assets. Jazz Pharmaceuticals shall provide assistance to GSK, on a level commensurate to the assistance provided by GSK
to Jazz Pharmaceuticals pursuant to Section 2.2 and 2.3, to transfer and assign the Purchased Assets to GSK. In addition, Jazz Pharmaceuticals shall transfer to GSK all data generated by Jazz Pharmaceuticals regarding the Purchased Assets prior
to termination by GSK pursuant to Section 9.2(a). 
 9.3 Survival. Termination of this Agreement will terminate all outstanding obligations and
liabilities between the Parties arising from this Agreement except those described in Sections 2.1, 2.3, 2.5, 2.6 (except with respect to termination pursuant to Section 9.2(c)), 4.3, 4.4, 6.1, 6.2 and 9.2(b) and (c), 9.3, and Articles 1, 7, 8,
10, 11, and 12. Additionally, any other provision required to interpret and enforce the Parties’ rights and obligations under this Agreement will also survive, but only to the extent required for the full observation and performance of this
Agreement. 
 ARTICLE 10—DISPUTE RESOLUTION 
 10.1 Disputes. The Parties recognize that disputes as to certain matters may from time to time arise that relate to either Party’s rights or obligations hereunder. It is the objective of the Parties to establish procedures to
facilitate the resolution of disputes arising under this Agreement in an expedited manner by mutual cooperation. To accomplish this objective, the Parties agree to follow the following procedures if and when a dispute arises under this Agreement:

 (a) Any such disputes will be first referred by either Party to senior representatives designated by each Party. If such senior
representatives are unable to resolve such a dispute within thirty (30) days of being requested by a Party to resolve the dispute, the matter will be presented to the chief executive officers of Jazz Pharmaceuticals and GSK, for resolution
through good faith discussions. In the event that the chief executive officers of Jazz Pharmaceuticals and GSK cannot resolve the dispute within thirty (30) days of being requested by a Party to resolve a dispute, either Party may, by written
notice to the other, invoke the mediation provisions of Section 10.1(b). 
 (b) Upon invocation as provided by Section 10.1(a), the
Parties agree to try in good faith to resolve such dispute by non-binding mediation administered by the Center for Public Resources (“CPR”) in accordance with the then current CPR Model Procedure for Mediation of Business Disputes,
provided that specific provisions of this Section 10.1(a) will override inconsistent provisions of such CPR Model Procedure. The mediator will be selected from the CPR Panel of Neutrals and the location of the mediation be selected by mutual
agreement of the Parties, and absent such mutual agreement, will be New York, New York. If the Parties cannot agree upon the selection of the mediator or its location within ten (10) Business Days of the initiation of the mediation, then CPR
will appoint the mediator and the mediator will select the location. The Parties will attempt to resolve such dispute through mediation until one of the following occurs: (i) the Parties reach a written settlement; (ii) the mediator
notifies the Parties in writing that 

  

 25 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 
they have reached an impasse; (iii) the Parties agree in writing that they have reached an impasse; or (iv) the Parties have not reached a
settlement within sixty (60) days of the initiation of the mediation. All aspects of any such mediation, including any resolution or decision relating thereto, will be non-binding, and will be held as confidential and all participants,
including the mediator, will be bound by judicially enforceable obligations of strict confidentiality except to the extent the Parties agree in writing to waive in whole or part such confidentiality. 
 (c) If the Parties fail to resolve such dispute through mediation, then either Party may take such other action as such Party deems appropriate in its
sole discretion, including pursuing litigation against the other Party. 
 10.2 Injunctive Relief. Notwithstanding the foregoing dispute resolution
procedures, in the event of an actual or threatened breach hereunder, the aggrieved Party may seek restraining orders, specific performance or other injunctive relief without submitting to such dispute resolution procedure. 
 10.3 Tolling. The Parties agree that all applicable statutes of limitation and time-based defenses (such as estoppel and laches) will be tolled while the
procedures set forth in this Article 10 are pending, and the Parties will cooperate in taking any and all actions necessary to achieve such a result. 
 ARTICLE 11—CONFIDENTIALITY 
 11.1 “Confidential Information” means all information disclosed by a Party to the
other Party that would reasonably be regarded as of a confidential or commercially sensitive nature by the disclosing Party, including any matter relating to or arising in connection with this Agreement or the business or affairs of the disclosing
Party. Without limitation, Confidential Information will include any confidential or commercially sensitive information relating to Jazz Pharmaceuticals and GSK and any of its or their Affiliates. For purposes of clarification, up to and on the Time
of Closing, the Purchased Assets will be deemed the Confidential Information of GSK and thereafter will be deemed the Confidential Information of Jazz Pharmaceuticals and no longer the Confidential Information of GSK. 
  

	11.2	Exclusions. Confidential Information excludes the following: 

 (a) information which at the time of disclosure hereunder is already in the public domain; 
 (b) information
which becomes available to the public after the date of disclosure hereunder through no fault of the receiving Party; 
 (c) information which
the receiving Party can demonstrate by written records that (i) it already possessed without any confidentiality obligation therefore at the time of receipt thereof from the disclosing Party or (ii) it or its employees independently
developed without use of, or reliance on, the disclosing Party’s Confidential Information; or 
 (d) information which the receiving
Party receives from a Third Party which has no confidentiality obligation to the disclosing Party and duly possesses it. 
  

 26 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 11.3 Disclosure Required By Law. Notwithstanding the foregoing, Confidential Information may be disclosed to the
extent required by law, regulation or order of a competent authority (including any regulatory or governmental body or securities exchange) to be disclosed by the receiving Party; provided that, where practicable, the disclosing Party is given
reasonable advance notice of the intended disclosure and the right to attempt to protect the confidentiality of the Confidential Information before any governmental agency. 
 11.4 Confidential Information and the Grantback License. With respect to Confidential Information of Jazz Pharmaceuticals that may be necessary for GSK to exercise or sublicense the Grantback License, GSK, its
Affiliates and sublicensees will maintain the confidentiality of such Confidential Information, and will only use such Confidential Information as may be required to exercise the Grantback License or sublicense thereof. 
 11.5 Publicity. Each of the Parties hereto agrees not to disclose to any Third Party the financial or other material terms of this Agreement without the prior
written consent of the other Party hereto, except to advisors, investors and others on a need-to-know basis under circumstances that reasonably ensure the confidentiality thereof, or to the extent required by law. 
 11.6 Publications. After the Closing Date [ * ] shall submit any proposed publication (or other public disclosure, such as a lecture, presentation or
seminar) related to the Purchased Assets containing Confidential Information of [ * ] at least sixty (60) days prior to the proposed publication or public disclosure, to allow [ * ] to review such planned publication or public
disclosure. [ * ] shall promptly review such proposed publication and respond in any event in writing to [ * ] within forty-five (45) days and make any objections that it may have to the publication or public disclosure of
Confidential Information contained therein and if no response is received from [ * ] within such forty-five (45) day period, [ * ] may conclusively presume that the publication may proceed without delay. Should [ * ] make
an objection to the publication or public disclosure of any such Confidential Information, then [ * ] will have no right to include the Confidential Information in such publication or public disclosure. 
 ARTICLE 12—MISCELLANEOUS 
 12.1 Assignment. This
Agreement will not be assignable by either Party to any Third Party without the written consent of the other Party hereto. Notwithstanding the foregoing, either Party may assign this Agreement, without the written consent of the other Party, to an
Affiliate or to an entity that acquires all or substantially all of the business or assets of such Party to which this Agreement pertains in connection with a merger, acquisition, sale or similar reorganization or the sale of all or substantially
all of its assets or the sale of all or substantially all of its pharmaceutical and/or healthcare assets, and such Third Party agrees in writing to be bound by the terms and conditions of this Agreement. This Agreement will survive any such merger,
acquisition or reorganization of either Party with or into, or such sale of assets to, another Third Party and no consent for such merger, acquisition, reorganization or sale will be required hereunder. This Agreement will be binding upon and inure
to the benefit of the successors and permitted assigns of the Parties. Any assignment not in accordance with this Agreement will be void. 
 12.2
Consent/Approval. Whenever provision is made in this Agreement for either Party to secure the consent or approval of the other, that consent or approval will not unreasonably be withheld, and whenever in this Agreement provision is made for
one Party to object to or disapprove a matter, such objection or disapproval will not unreasonably be exercised. 
  

 27 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 12.3 Force Majeure. Neither Party will lose any rights hereunder or be liable to the other Party for damages or
losses on account of failure of performance by the defaulting Party if the failure is occasioned by government action, war, fire, earthquake, explosion, flood, strike, lockout, embargo, act of God, or any other similar or dissimilar cause beyond the
control of the defaulting Party, provided that the Party claiming force majeure has exerted all reasonable efforts to avoid or remedy such force majeure. 
 12.4 Notices. All notices hereunder will be in writing and will be deemed given if delivered personally or by facsimile transmission (receipt verified), telexed, mailed by registered or certified mail (return receipt requested),
postage prepaid, or sent by express courier service, to the Parties at the following addresses (or at such other address for a Party as will be specified by like notice; provided, that notices of a change of address will be effective only upon
receipt thereof). Further, any notice given by GGL and/or SB under this Agreement shall be deemed to have been given by GSK. 
  

			
	If to Jazz Pharmaceuticals:	  	
		
	 Jazz Pharmaceuticals
	  	
	 3180 Porter Drive
	  	
	 Palo Alto, CA 94304
	  	
	 U.S.A.
	  	
	 Attn: General Counsel
	  	
	 Fax: 650.496.3781
	  	
		
	If to GGL:	  	If to SB:
		
	 Glaxo Group Limited
	  	 SmithKline Beecham Corporation

	 Glaxo Wellcome House
	  	 One Franklin Plaza

	 Berkeley Avenue
	  	 P.O. Box 7929

	 Greenford, Middlesex, UB6 0NN,
	  	 Philadelphia, PA 19101

	 UK
	  	 U.S.A.

	 Attn: Corporate Secretary
	  	 Attn: Corporate Secretary

	 Fax: 011.44.(0).20.8047.6904
	  	 Fax: 215.751.5349

		
	with a copy to:	  	
		
	 GlaxoSmithKline
	  	
	 709 Swedeland Road
	  	
	 King of Prussia, PA 19406
	  	
	 UW 2214
	  	
	 U.S.A.
	  	
	 Attn: Head, Ventures Investment

	 Fax: 610.270.6299
	  	
		
	 and
	  	

  

 28 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

			
	 GlaxoSmithKline
	  	
	 2301 Renaissance Blvd, RN0510
	  	
	 King of Prussia, PA 19406
	  	
	 U.S.A.
	  	
	 Attn: SVP and Associate General Counsel

	 R&D Legal Operations

	 Fax: 610.787.7084
	  	

 12.5 No Waiver. The waiver from time to time by either of the Parties of any of their rights or their
failure to exercise any remedy will not operate or be construed as a continuing waiver of same or of any other of such Party’s rights or remedies provided in this Agreement or excuse a similar subsequent failure to perform any such term or
condition. Neither Party may waive or release any of its rights or interests in this Agreement except in writing. 
 12.6 Invalidity of
Provisions/Severability. If any term, covenant or condition of this Agreement or the application thereof to any Party or circumstance will, to any extent, be held to be invalid or unenforceable, then (i) the remainder of this Agreement, or
the application of such term, covenant or condition to Parties or circumstances other than those as to which it is held invalid or unenforceable, will not be affected thereby and each term, covenant or condition of this Agreement will be valid and
be enforced to the fullest extent permitted by law; and (ii) the Parties hereto covenant and agree to renegotiate any such term, covenant or application thereof in good faith in order to provide a reasonably acceptable alternative to the term,
covenant or condition of this Agreement or the application thereof that is invalid or unenforceable, it being the intent of the Parties that the basic purposes of this Agreement are to be effectuated. 
 12.7 Entire Agreement. This Agreement, including the Schedules and hereto, constitutes the entire agreement between the Parties with respect to the transactions
provided for herein and, except as stated in this Agreement and in the instruments and documents to be executed and delivered pursuant hereto, contains all of the agreements between the Parties and there are no verbal agreements or understandings
between the Parties not reflected in this Agreement. This Agreement may not be amended or modified in any respect except by written instrument executed by each of the Parties. 
 12.8 Governing Law. This Agreement and any dispute arising from the performance or breach hereof will be governed by and construed and enforced in accordance with the laws of the State of New York, U.S.,
without reference to conflicts of laws principles. 
 12.9 Performance Warranty. Each Party hereby warrants and guarantees the performance of any and
all rights and obligations by its Affiliate(s). 
 12.10 Independent Contractors. Nothing herein will be construed to create any relationship of
employer and employee, agent and principal, partnership or joint venture between the Parties. Each Party is an independent contractor. Neither Party will assume, either directly or indirectly, any liability of or for the other Party. Neither Party
will have the authority to bind or obligate the other Party and neither Party will represent that it has such authority. 
 12.11 Headings. Headings
used herein are for convenience only and will not in any way affect the construction of or be taken into consideration in interpreting this Agreement. The Recitals and Annexes to this Agreement constitute an integral part of this Agreement. In the
event of 

  

 29 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 
any conflict or inconsistency between any of the terms and conditions of this Agreement, the conflict or inconsistency will be resolved according to the
following order or priority: The Sections of the Agreement, the Annexes and the Recitals. 
 12.12 Payment of Transaction Expenses. All legal fees and
other expenses incurred on behalf of GSK in connection with the negotiation of this Agreement and the consummation of the transactions contemplated herein will be borne by GSK, whether or not the Time of Closing shall have occurred. All legal fees
and other expenses incurred on behalf of Jazz Pharmaceuticals in connection with the negotiation of this Agreement and the consummation of the transactions contemplated herein will be borne by Jazz Pharmaceuticals, whether or not the Time of Closing
shall have occurred. 
 12.13 Remedies Cumulative. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party
will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. If any action at law or in
equity is necessary to enforce or interpret the terms of this Agreement, the prevailing Party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to which such Party may be
entitled. 
 12.14 Specific Performance. The Parties hereto agree that irreparable damage would occur in the event any provision of this Agreement was
not performed in accordance with the terms hereof and that the Parties shall be entitled to specific performance of the terms hereof in addition to any other remedy at law or in equity. 
 12.15 Further Assurances. Each Party hereto shall execute and cause to be delivered to each other Party hereto such instruments and other documents, and shall take such other actions, as such other Party may
reasonably request (prior to, at or after the Time of Closing) for the purpose of carrying out or evidencing any of the transactions contemplated by this Agreement. 
 12.16 Challenges by Each Party to the Agreement. Each of the Parties agrees that neither it nor any Affiliate will initiate or prosecute, or encourage or assist directly or indirectly any Third Party in
initiating or prosecuting, any lawsuit attempting to challenge the validity of the transactions undertaken pursuant to this Agreement under any applicable law. In addition, GSK agrees that neither it nor any Affiliate shall seek to contest, or
encourage or assist directly or indirectly any Third Party in contesting, the transfer of the Purchased Assets to Jazz Pharmaceuticals pursuant to this Agreement under any applicable law. Jazz Pharmaceuticals agrees that neither it nor any Affiliate
shall seek to contest, or encourage or assist directly or indirectly any Third Party in contesting, the payment obligations of Jazz Pharmaceuticals to GSK hereunder under any applicable law. 
  

 30 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 12.17 Finder’s Fee. Each Party represents that it neither is, nor will be, obligated for any finder’s
fee or commission in connection with this transaction. GSK agrees to indemnify and to hold harmless Jazz Pharmaceuticals from any liability for any commission or compensation in the nature of a finders’ fee (and the costs and expenses of
defending against such liability or asserted liability) for which GSK or any of its officers, partners, employees, or representatives is responsible. Jazz Pharmaceuticals agrees to indemnify and to hold harmless GSK from any liability for any
commission or compensation in the nature of a finders’ fee (and the costs and expenses of defending against such liability or asserted liability) for which Jazz Pharmaceuticals or any of its officers, employees or representatives is
responsible. 
 12.18 Counterparts. This Agreement may be executed in two counterparts, each of which will be deemed an original, and all of which
together, will constitute one and the same instrument. 
 {Signatures continue on next page.} 
  

 31 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 IN WITNESS WHEREOF, the Parties have executed this Asset Purchase Agreement in duplicate originals by
their duly authorized representatives as of the Effective Date. 
  

							
	GLAXO GROUP LIMITED	 	JAZZ PHARMACEUTICALS, INC.
				
	By:	 	 /s/ S. M. Bicknell
	 	By:	 	 /s/ Carol Gamble

	Name:	 	S. M. Bicknell	 	Name:	 	Carol Gamble
	Title:	 	Company Secretary	 	Title:	 	Senior Vice President and General Counsel
			
	 SMITHKLINE BEECHAM CORPORATION
 d/b/a GLAXOSMITHKLINE
	 		 	
				
	By:	 	 /s/ Donald F. Parman
	 		 	
	Name:	 	Donald F. Parman	 		 	
	Title:	 	Vice President and Secretary	 		 	

  

 32 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 SCHEDULE 1.1.20 
 Chemical Structure of GW273293 
 [ * ] 
  

 33 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 SCHEDULE 1.1.29 
 PATENTS TRANSFERRED TO JAZZ PHARMACEUTICALS 
 [ * ] 
 GW273293 [ * ] 
 [ * ] 
 Second Priority Application for [ * ] 
  

									
	 Country
	  	 App./Date
	  	App.Date	  	Patent No.	  	 Status/
 Grant Date

	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]

 [ * ] GW273293 Process Case 
  

									
	 Country
	  	 App./Date
	  	App.Date	  	Patent No.	  	 Status/
 Grant Date

	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]

  

 34 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 SCHEDULE 2.6 
 Licensed GSK Patents 
 [ * ] 
  

									
	 Country
	  	 App No.
	  	App.Date	  	Patent No.	  	 Status/
 Grant Date

	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]

 [ * ] 
  

									
	 Country
	  	 App No.
	  	App.Date	  	Patent No.	  	 Status/
 Grant Date

	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]

  

 35 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 SCHEDULE 1.1.35 
 PURCHASED ASSETS 
 CLINICAL 
  

									
	 #
	  	Title	 	Author	 	Identifier	 	Date
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]

  

									
	PRECLINICAL TOXICITY, SAFETY AND EFFICACY
					
	 #
	  	Title	 	Author	 	Identifier	 	Date
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]

  

									
	CHEMICAL AND PHARMACEUTICAL DEVELOPMENT
					
	 #
	  	Title	 	Author	 	Identifier	 	Issue Date
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]

  

 36 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 SCHEDULE 1.1.35(c) 
 Quantities of GW273293 and other Compounds 
 Transferred to Jazz
Pharmaceuticals 
 [ * ] 
  

 37 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 SCHEDULE A 
 BILL OF SALE 
 This is a BILL OF SALE
from Glaxo Group Limited, a company incorporated under the laws of England and Wales with its registered offices at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN England (“GGL”) and SmithKline Beecham Corporation,
d/b/a GlaxoSmithKline, a company incorporated under the laws of the Commonwealth of Pennsylvania with offices at One Franklin Plaza, 200 North 16th Street, Philadelphia, Pennsylvania 19101 U.S.A. (“SB”) (GGL and SB are collectively referred to in this Bill of Sale as “GSK”) to Jazz Pharmaceuticals, Inc., a company incorporated
under the laws of the State of Delaware with offices at 630 Hansen Way, Palo Alto, California 94304 U.S., (“Jazz Pharmaceuticals”) pursuant to that certain Asset Purchase Agreement dated October 4, 2004 by and between GSK and Jazz
Pharmaceuticals (the “Agreement”). 
 For good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, GSK hereby sells, assigns, transfers, conveys, delivers and contributes to Jazz Pharmaceuticals, its successors and assigns, to have and to hold forever, all of its right, title and interest in and to the Purchased Assets (as defined
in the Agreement), subject to all of the other provisions contained in the Agreement. 
 From and after the Closing Date (as defined in the
Agreement) upon request of Jazz Pharmaceuticals, GSK will duly execute, acknowledge and deliver all such further acts, deeds, assignments, transfers, conveyances, powers of attorney and assurances as may be reasonably required to convey to and vest
the Purchased Assets in Jazz Pharmaceuticals or its permitted assignees and as may be appropriate to protect Jazz Pharmaceuticals’ rights, title and interest in and enjoyment of all the Purchased Assets and as may be appropriate otherwise to
carry out the transactions contemplated by the Agreement and this Bill of Sale. 
  

 38 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 IN WITNESS WHEREOF, and intending to be legally bound, the undersigned has duly executed and delivered
this Bill of Sale as of                     , 2004. 
  

							
	GLAXO GROUP LIMITED	 	JAZZ PHARMACEUTICALS, INC.
				
	By:	 	  
	 	By:	 	  

	Name:	 	  
	 	Name:	 	  

	Title:	 	  
	 	Title:	 	  

			
	 SMITHKLINE BEECHAM CORPORATION
	 		 	
	 d/b/a GLAXOSMITHKLINE
	 		 	
				
	 By:
	 	  
	 		 	
	 Name:
	 	  
	 		 	
	 Title:
	 	  
	 		 	

  

 39 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 SCHEDULE B 
 ASSIGNMENT OF PATENT RIGHTS 
 Glaxo
Group Limited, a company incorporated under the laws of England and Wales with offices at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN England (“GGL”) and SmithKline Beecham Corporation d/b/a GlaxoSmithKline, a
company incorporated under the laws of the Commonwealth of Pennsylvania with offices at One Franklin Plaza, 200 North 16th Street, Philadelphia, Pennsylvania 19101 U.S.A. (“SB”) (GGL and SB are collectively referred to in this Assignment as “Assignor”), hereby assign certain patent rights to Jazz Pharmaceuticals, Inc., a company
incorporated under the laws of the State of Delaware with offices at 630 Hansen Way, Palo Alto, California 94304 (“Assignee”). 
 Whereas, Assignor is the sole owner of the United States and foreign patents set forth on Exhibit 1 hereto (the “Patents”); and 
 Whereas, Assignor has agreed with Assignee for the transfer to it of Assignor’s whole right, title and interest in and to such Patents and inventions described and/or claimed therein. 
 Now This Assignment Witnesseth that, for the consideration provided for in, and pursuant to that certain Asset Purchase Agreement between the Assignor
and the Assignee dated October 4, 2004, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor, as beneficial owner, hereby assign and transfer to Assignee with full title guarantee the
whole right, title and interest in and to the Patents covering the Purchased Assets, and any and all other patents in the United States of America or other countries which may be granted therefore and thereon, and in and to any and all reissues or
extensions of the Patents or of such other patents, and the full exclusive benefits thereof, and all rights, privileges and advantages appertaining thereto, including the right to claim priority therefrom, including any and all rights to damages,
profits or recoveries of any nature for past infringement of the Patents, and the payment of any and all maintenance fees, taxes, and the like, to hold the same unto and to the use of Assignee, its successors and assigns absolutely during the
residue of the respective terms for which the Patents and such other patents were granted and during any such terms. 
 Assignor hereby
covenants that Assignor has not executed and will not execute any agreements inconsistent with this Assignment. 
  

 40 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 Promptly upon Assignee’s written request, Assignor hereby agrees to execute such additional form(s)
of assignment for the foregoing Patents covering the Purchased Assets as may be required by the appropriate governmental authority of the United States of America or any foreign country for recordation of this Assignment. Without limitation,
Assignor grants to Assignee the power to insert on this Assignment any further identification that may be necessary or desirable in order to record this Assignment. 
 Executed at                     ,
                     this      day of
                     2004. 
  

			
	 GLAXO GROUP LIMITED

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

 Executed at
                    ,
                     this      day of
                     2004. 
  

			
	 SMITHKLINE BEECHAM CORPORATION

	 d/b/a GLAXOSMITHKLINE

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

  

 41 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 EXHIBIT 1 TO SCHEDULE B OF THE ASSET PURCHASE AGREEMENT 
 ASSIGNMENT OF PATENT RIGHTS 
 Assignor and Assignee hereby agree that this Exhibit 1 shall be identical to Schedule A to the Agreement. Assignee shall have the right to prepare multiple versions of this Exhibit 1 that list one or more of the Patents for a single country
set forth on Schedule A for recordation with the appropriate governmental authority of such country. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF
THE SECURITIES ACT OF 1933, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}]]